1d5r › Citations

Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP
Cell 99 323-34 (1999)
Cited: 691 times
EuropePMC logo PMID: 10555148

Abstract

The PTEN tumor suppressor is mutated in diverse human cancers and in hereditary cancer predisposition syndromes. PTEN is a phosphatase that can act on both polypeptide and phosphoinositide substrates in vitro. The PTEN structure reveals a phosphatase domain that is similar to protein phosphatases but has an enlarged active site important for the accommodation of the phosphoinositide substrate. The structure also reveals that PTEN has a C2 domain. The PTEN C2 domain binds phospholipid membranes in vitro, and mutation of basic residues that could mediate this reduces PTEN's membrane affinity and its ability to suppress the growth of glioblastoma tumor cells. The phosphatase and C2 domains associate across an extensive interface, suggesting that the C2 domain may serve to productively position the catalytic domain on the membrane.

Reviews - 1d5r mentioned but not cited (15)

  1. A continuum model for tumour suppression. Berger AH, Knudson AG, Pandolfi PP. Nature 476 163-169 (2011)
  2. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Uversky VN, Davé V, Iakoucheva LM, Malaney P, Metallo SJ, Pathak RR, Joerger AC. Chem Rev 114 6844-6879 (2014)
  3. PTEN modulators: a patent review. Boosani CS, Agrawal DK. Expert Opin Ther Pat 23 569-580 (2013)
  4. The structure of phosphoinositide phosphatases: Insights into substrate specificity and catalysis. Hsu F, Mao Y. Biochim Biophys Acta 1851 698-710 (2015)
  5. Targeting phosphatases of regenerating liver (PRLs) in cancer. Wei M, Korotkov KV, Blackburn JS. Pharmacol Ther 190 128-138 (2018)
  6. Membrane association of the PTEN tumor suppressor: neutron scattering and MD simulations reveal the structure of protein-membrane complexes. Nanda H, Heinrich F, Lösche M. Methods 77-78 136-146 (2015)
  7. Unique carbohydrate binding platforms employed by the glucan phosphatases. Emanuelle S, Brewer MK, Meekins DA, Gentry MS. Cell Mol Life Sci 73 2765-2778 (2016)
  8. Critical Roles of Dual-Specificity Phosphatases in Neuronal Proteostasis and Neurological Diseases. Bhore N, Wang BJ, Chen YW, Liao YF. Int J Mol Sci 18 E1963 (2017)
  9. Structural mechanisms of plant glucan phosphatases in starch metabolism. Meekins DA, Vander Kooi CW, Gentry MS. FEBS J 283 2427-2447 (2016)
  10. Voltage sensitive phosphatases: emerging kinship to protein tyrosine phosphatases from structure-function research. Hobiger K, Friedrich T. Front Pharmacol 6 20 (2015)
  11. Overview of protein structural and functional folds. Sun PD, Foster CE, Boyington JC. Curr Protoc Protein Sci Chapter 17 Unit 17.1 (2004)
  12. The Impact of Genetic Variants on PTEN Molecular Functions and Cellular Phenotypes. Hasle N, Matreyek KA, Fowler DM. Cold Spring Harb Perspect Med 9 a036228 (2019)
  13. Targeting PTEN Regulation by Post Translational Modifications. González-García A, Garrido A, Carrera AC. Cancers (Basel) 14 5613 (2022)
  14. Domain-to-domain coupling in voltage-sensing phosphatase. Sakata S, Matsuda M, Kawanabe A, Okamura Y. Biophys Physicobiol 14 85-97 (2017)
  15. Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. Moshawih S, Lim AF, Ardianto C, Goh KW, Kifli N, Goh HP, Jarrar Q, Ming LC. Biomolecules 12 878 (2022)

Articles - 1d5r mentioned but not cited (95)

  1. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Cancer Discov 4 80-93 (2014)
  2. Automated builder and database of protein/membrane complexes for molecular dynamics simulations. Jo S, Kim T, Im W. PLoS One 2 e880 (2007)
  3. Multiplex assessment of protein variant abundance by massively parallel sequencing. Matreyek KA, Starita LM, Stephany JJ, Martin B, Chiasson MA, Gray VE, Kircher M, Khechaduri A, Dines JN, Hause RJ, Bhatia S, Evans WE, Relling MV, Yang W, Shendure J, Fowler DM. Nat Genet 50 874-882 (2018)
  4. A Saturation Mutagenesis Approach to Understanding PTEN Lipid Phosphatase Activity and Genotype-Phenotype Relationships. Mighell TL, Evans-Dutson S, O'Roak BJ. Am J Hum Genet 102 943-955 (2018)
  5. Structure-based reassessment of the caveolin signaling model: do caveolae regulate signaling through caveolin-protein interactions? Collins BM, Davis MJ, Hancock JF, Parton RG. Dev Cell 23 11-20 (2012)
  6. Evaluating caveolin interactions: do proteins interact with the caveolin scaffolding domain through a widespread aromatic residue-rich motif? Byrne DP, Dart C, Rigden DJ. PLoS One 7 e44879 (2012)
  7. Prediction of reversibly oxidized protein cysteine thiols using protein structure properties. Sanchez R, Riddle M, Woo J, Momand J. Protein Sci 17 473-481 (2008)
  8. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB. Cancer Cell 35 504-518.e7 (2019)
  9. Formin homology 2 domains occur in multiple contexts in angiosperms. Cvrcková F, Novotný M, Pícková D, Zárský V. BMC Genomics 5 44 (2004)
  10. The role of hydrophobic interactions in positioning of peripheral proteins in membranes. Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI. BMC Struct Biol 7 44 (2007)
  11. Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure. Tokheim C, Bhattacharya R, Niknafs N, Gygax DM, Kim R, Ryan M, Masica DL, Karchin R. Cancer Res 76 3719-3731 (2016)
  12. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study. Yang L, Wang K, Chen J, Jegga AG, Luo H, Shi L, Wan C, Guo X, Qin S, He G, Feng G, He L. PLoS Comput Biol 7 e1002016 (2011)
  13. Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN. Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R. Neoplasia 17 367-373 (2015)
  14. Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis. Shearn CT, Smathers RL, Backos DS, Reigan P, Orlicky DJ, Petersen DR. Free Radic Biol Med 65 680-692 (2013)
  15. Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium. Cheung LW, Walkiewicz KW, Besong TM, Guo H, Hawke DH, Arold ST, Mills GB. Elife 4 e06866 (2015)
  16. PTEN regulates RPA1 and protects DNA replication forks. Wang G, Li Y, Wang P, Liang H, Cui M, Zhu M, Guo L, Su Q, Sun Y, McNutt MA, Yin Y. Cell Res 25 1189-1204 (2015)
  17. Crystal structure of the cytoplasmic phosphatase and tensin homolog (PTEN)-like region of Ciona intestinalis voltage-sensing phosphatase provides insight into substrate specificity and redox regulation of the phosphoinositide phosphatase activity. Matsuda M, Takeshita K, Kurokawa T, Sakata S, Suzuki M, Yamashita E, Okamura Y, Nakagawa A. J Biol Chem 286 23368-23377 (2011)
  18. A glutamate switch controls voltage-sensitive phosphatase function. Liu L, Kohout SC, Xu Q, Müller S, Kimberlin CR, Isacoff EY, Minor DL. Nat Struct Mol Biol 19 633-641 (2012)
  19. Structural and functional analysis of PTPMT1, a phosphatase required for cardiolipin synthesis. Xiao J, Engel JL, Zhang J, Chen MJ, Manning G, Dixon JE. Proc Natl Acad Sci U S A 108 11860-11865 (2011)
  20. The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. Stehr H, Jang SH, Duarte JM, Wierling C, Lehrach H, Lappe M, Lange BM. Mol Cancer 10 54 (2011)
  21. Structural bioinformatics prediction of membrane-binding proteins. Bhardwaj N, Stahelin RV, Langlois RE, Cho W, Lu H. J Mol Biol 359 486-495 (2006)
  22. p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, Jeong SY, Hwang JJ, Lee SJ, Suh YA, Kim I, Nam KY, Han S, Kim JE, Kim KP, Hong YS, Lee JL, Lee WJ, Choi EK, Lee JS, Jin DH, Kim TW. Cell Death Differ 21 146-160 (2014)
  23. Conformational Dynamics and Allosteric Regulation Landscapes of Germline PTEN Mutations Associated with Autism Compared to Those Associated with Cancer. Smith IN, Thacker S, Seyfi M, Cheng F, Eng C. Am J Hum Genet 104 861-878 (2019)
  24. Understanding the Origins of Loss of Protein Function by Analyzing the Effects of Thousands of Variants on Activity and Abundance. Cagiada M, Johansson KE, Valanciute A, Nielsen SV, Hartmann-Petersen R, Yang JJ, Fowler DM, Stein A, Lindorff-Larsen K. Mol Biol Evol 38 3235-3246 (2021)
  25. Interactions of phosphatase and tensin homologue (PTEN) proteins with phosphatidylinositol phosphates: insights from molecular dynamics simulations of PTEN and voltage sensitive phosphatase. Kalli AC, Devaney I, Sansom MS. Biochemistry 53 1724-1732 (2014)
  26. Molecular Features of Phosphatase and Tensin Homolog (PTEN) Regulation by C-terminal Phosphorylation. Chen Z, Dempsey DR, Thomas SN, Hayward D, Bolduc DM, Cole PA. J Biol Chem 291 14160-14169 (2016)
  27. Membrane association of the PTEN tumor suppressor: electrostatic interaction with phosphatidylserine-containing bilayers and regulatory role of the C-terminal tail. Shenoy SS, Nanda H, Lösche M. J Struct Biol 180 394-408 (2012)
  28. Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior. Anastasio NC, Gilbertson SR, Bubar MJ, Agarkov A, Stutz SJ, Jeng Y, Bremer NM, Smith TD, Fox RG, Swinford SE, Seitz PK, Charendoff MN, Craft JW, Laezza FM, Watson CS, Briggs JM, Cunningham KA. J Neurosci 33 1615-1630 (2013)
  29. Defining the membrane-associated state of the PTEN tumor suppressor protein. Lumb CN, Sansom MS. Biophys J 104 613-621 (2013)
  30. Redox Modulation of PTEN Phosphatase Activity by Hydrogen Peroxide and Bisperoxidovanadium Complexes. Lee CU, Hahne G, Hanske J, Bange T, Bier D, Rademacher C, Hennig S, Grossmann TN. Angew Chem Int Ed Engl 54 13796-13800 (2015)
  31. Phospholipid-binding sites of phosphatase and tensin homolog (PTEN): exploring the mechanism of phosphatidylinositol 4,5-bisphosphate activation. Wei Y, Stec B, Redfield AG, Weerapana E, Roberts MF. J Biol Chem 290 1592-1606 (2015)
  32. CAGI5: Objective performance assessments of predictions based on the Evolutionary Action equation. Katsonis P, Lichtarge O. Hum Mutat 40 1436-1454 (2019)
  33. CRISPR-Cas9 human gene replacement and phenomic characterization in Caenorhabditis elegans to understand the functional conservation of human genes and decipher variants of uncertain significance. McDiarmid TA, Au V, Loewen AD, Liang J, Mizumoto K, Moerman DG, Rankin CH. Dis Model Mech 11 dmm036517 (2018)
  34. Conformational stability and catalytic activity of PTEN variants linked to cancers and autism spectrum disorders. Johnston SB, Raines RT. Biochemistry 54 1576-1582 (2015)
  35. Dynamics and structural stability effects of germline PTEN mutations associated with cancer versus autism phenotypes. Smith IN, Thacker S, Jaini R, Eng C. J Biomol Struct Dyn 37 1766-1782 (2019)
  36. The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane. Jang H, Smith IN, Eng C, Nussinov R. iScience 24 102438 (2021)
  37. Cryo-electron microscopy structure and analysis of the P-Rex1-Gβγ signaling scaffold. Cash JN, Urata S, Li S, Ravala SK, Avramova LV, Shost MD, Gutkind JS, Tesmer JJG, Cianfrocco MA. Sci Adv 5 eaax8855 (2019)
  38. Regulation of the activity of the tumor suppressor PTEN by thioredoxin in Drosophila melanogaster. Song Z, Saghafi N, Gokhale V, Brabant M, Meuillet EJ. Exp Cell Res 313 1161-1171 (2007)
  39. Structural and biochemical characterization of Siw14: A protein-tyrosine phosphatase fold that metabolizes inositol pyrophosphates. Wang H, Gu C, Rolfes RJ, Jessen HJ, Shears SB. J Biol Chem 293 6905-6914 (2018)
  40. Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer. Smith IN, Briggs JM. Proteins 84 1625-1643 (2016)
  41. The structural basis of PTEN regulation by multi-site phosphorylation. Dempsey DR, Viennet T, Iwase R, Park E, Henriquez S, Chen Z, Jeliazkov JR, Palanski BA, Phan KL, Coote P, Gray JJ, Eck MJ, Gabelli SB, Arthanari H, Cole PA. Nat Struct Mol Biol 28 858-868 (2021)
  42. scyllo-inositol pentakisphosphate as an analogue of myo-inositol 1,3,4,5,6-pentakisphosphate: chemical synthesis, physicochemistry and biological applications. Riley AM, Trusselle M, Kuad P, Borkovec M, Cho J, Choi JH, Qian X, Shears SB, Spiess B, Potter BV. Chembiochem 7 1114-1122 (2006)
  43. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA. Joshi R, Qin L, Cao X, Zhong S, Voss C, Min W, Li SSC. J Biol Chem 295 645-656 (2020)
  44. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells. Chen J, Mu Q, Li X, Yin X, Yu M, Jin J, Li C, Zhou Y, Zhou J, Suo S, Lu D, Jin J. Oncotarget 8 40318-40326 (2017)
  45. Inhibition of Cell Proliferation and Metastasis by Scutellarein Regulating PI3K/Akt/NF-κB Signaling through PTEN Activation in Hepatocellular Carcinoma. Ha SE, Kim SM, Vetrivel P, Kim HH, Bhosale PB, Heo JD, Lee HJ, Kim GS. Int J Mol Sci 22 8841 (2021)
  46. New aspects of the phosphatase VHZ revealed by a high-resolution structure with vanadate and substrate screening. Kuznetsov VI, Hengge AC, Johnson SJ. Biochemistry 51 9869-9879 (2012)
  47. Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers. Serebriiskii IG, Pavlov V, Tricarico R, Andrianov G, Nicolas E, Parker MI, Newberg J, Frampton G, Meyer JE, Golemis EA. Nat Commun 13 1618 (2022)
  48. Herb-target virtual screening and network pharmacology for prediction of molecular mechanism of Danggui Beimu Kushen Wan for prostate cancer. Li H, Hung A, Yang AWH. Sci Rep 11 6656 (2021)
  49. On the intrinsic disorder status of the major players in programmed cell death pathways. Uversky AV, Xue B, Peng Z, Kurgan L, Uversky VN. F1000Res 2 190 (2013)
  50. Structural and functional characterization of a novel phosphatase from the Arabidopsis thaliana gene locus At1g05000. Aceti DJ, Bitto E, Yakunin AF, Proudfoot M, Bingman CA, Frederick RO, Sreenath HK, Vojtik FC, Wrobel RL, Fox BG, Markley JL, Phillips GN. Proteins 73 241-253 (2008)
  51. Binding of Ca2+-independent C2 domains to lipid membranes: A multi-scale molecular dynamics study. Larsen AH, Sansom MSP. Structure 29 1200-1213.e2 (2021)
  52. Linking protein structural and functional change to mutation using amino acid networks. Sotomayor-Vivas C, Hernández-Lemus E, Dorantes-Gilardi R. PLoS One 17 e0261829 (2022)
  53. Molecular Analysis of AFP and HSA Interactions with PTEN Protein. Zhu M, Lin B, Zhou P, Li M. Biomed Res Int 2015 256916 (2015)
  54. Rapid protein stability prediction using deep learning representations. Blaabjerg LM, Kassem MM, Good LL, Jonsson N, Cagiada M, Johansson KE, Boomsma W, Stein A, Lindorff-Larsen K. Elife 12 e82593 (2023)
  55. Molecular Docking Studies of a Cyclic Octapeptide-Cyclosaplin from Sandalwood. Mishra A, Dey S. Biomolecules 9 E740 (2019)
  56. Superdomains in the protein structure hierarchy: The case of PTP-C2. Haynie DT, Xue B. Protein Sci 24 874-882 (2015)
  57. Understanding the stereospecific interactions of 3-deoxyphosphatidylinositol derivatives with the PTEN phosphatase domain. Wang Q, Wei Y, Mottamal M, Roberts MF, Krilov G. J Mol Graph Model 29 102-114 (2010)
  58. A recessive form of extreme macrocephaly and mild intellectual disability complements the spectrum of PTEN hamartoma tumour syndrome. Schwerd T, Khaled AV, Schürmann M, Chen H, Händel N, Reis A, Gillessen-Kaesbach G, Uhlig HH, Abou Jamra R. Eur J Hum Genet 24 889-894 (2016)
  59. Formononetin induces vasorelaxation in rat thoracic aorta via regulation of the PI3K/PTEN/Akt signaling pathway. Li T, Zhong Y, Tang T, Luo J, Cui H, Fan R, Wang Y, Wang D. Drug Des Devel Ther 12 3675-3684 (2018)
  60. Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract. Han L, Cao X, Chen Z, Guo X, Yang L, Zhou Y, Bian H. BMC Complement Med Ther 20 57 (2020)
  61. Engineering FKBP-Based Destabilizing Domains to Build Sophisticated Protein Regulation Systems. An W, Jackson RE, Hunter P, Gögel S, van Diepen M, Liu K, Meyer MP, Eickholt BJ. PLoS One 10 e0145783 (2015)
  62. Proproliferative function of adaptor protein GRB10 in prostate carcinoma. Khan MI, Al Johani A, Hamid A, Ateeq B, Manzar N, Adhami VM, Lall RK, Rath S, Sechi M, Siddiqui IA, Choudhry H, Zamzami MA, Havighurst TC, Huang W, Ntambi JM, Mukhtar H. FASEB J 33 3198-3211 (2019)
  63. Structural and Dynamic Effects of PTEN C-Terminal Tail Phosphorylation. Smith IN, Dawson JE, Krieger J, Thacker S, Bahar I, Eng C. J Chem Inf Model 62 4175-4190 (2022)
  64. Synthesis, Biological Evaluation and Docking Studies of Benzoxazoles Derived from Thymoquinone. Glamočlija U, Padhye S, Špirtović-Halilović S, Osmanović A, Veljović E, Roca S, Novaković I, Mandić B, Turel I, Kljun J, Trifunović S, Kahrović E, Kraljević Pavelić S, Harej A, Klobučar M, Završnik D. Molecules 23 E3297 (2018)
  65. Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers. Matreyek KA, Stephany JJ, Ahler E, Fowler DM. Genome Med 13 165 (2021)
  66. Molecular Mechanism of Crataegi Folium and Alisma Rhizoma in the Treatment of Dyslipidemia Based on Network Pharmacology and Molecular Docking. Wang H, Wang H, Zhang J, Luo J, Peng C, Tong X, Chen X. Evid Based Complement Alternat Med 2022 4891370 (2022)
  67. Protein Chemical Approaches to Understanding PTEN Lipid Phosphatase Regulation. Dempsey DR, Cole PA. Methods Enzymol 607 405-422 (2018)
  68. Research on Quality Markers of Guizhi Fuling Prescription for Endometriosis Treatment Based on Gray Correlation Analysis Strategy. Chen J, Gai X, Xu X, Liu Y, Ren T, Liu S, Ma T, Tian C, Liu C. Front Pharmacol 11 588549 (2020)
  69. A126 in the active site and TI167/168 in the TI loop are essential determinants of the substrate specificity of PTEN. Leitner MG, Hobiger K, Mavrantoni A, Feuer A, Oberwinkler J, Oliver D, Halaszovich CR. Cell Mol Life Sci 75 4235-4250 (2018)
  70. Atropine Is a Suppressor of Epithelial-Mesenchymal Transition (EMT) That Reduces Stemness in Drug-Resistant Breast Cancer Cells. Ahmed EA, Alkuwayti MA, Ibrahim HM. Int J Mol Sci 23 9849 (2022)
  71. Incaspitolide A extracted from Carpesium cernuum induces apoptosis in vitro via the PI3K/AKT pathway in benign prostatic hyperplasia. Chen X, Song J, Yuan D, Rao Q, Jiang K, Feng S, Zhu G, Yan C, Li Y, Zhu J. Biosci Rep 41 BSR20210477 (2021)
  72. Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study. Mondal SK, Sen MK. Heliyon 6 e03106 (2020)
  73. Parallel Chemoselective Profiling for Mapping Protein Structure. Potter ZE, Lau HT, Chakraborty S, Fang L, Guttman M, Ong SE, Fowler DM, Maly DJ. Cell Chem Biol 27 1084-1096.e4 (2020)
  74. Shape shifting: The multiple conformational substates of the PTEN N-terminal PIP2 -binding domain. Dawson JE, Smith IN, Martin W, Khan K, Cheng F, Eng C. Protein Sci 31 e4308 (2022)
  75. Cytotoxicity of oleanane type triterpene from leaf extract of Pterospermum acerifolium (in vitro) and theoretical investigation of inhibitory signaling pathway. Rehan M, Shafiullah, Sultanat. Chin Herb Med 13 124-130 (2021)
  76. GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer. Murugan AK, Qasem E, Al-Hindi H, Alzahrani AS. Oncotarget 10 4107-4124 (2019)
  77. Insight into the PTEN - p85α interaction and lipid binding properties of the p85α BH domain. Marshall JDS, Mellor P, Ruan X, Whitecross DE, Moore SA, Anderson DH. Oncotarget 9 36975-36992 (2018)
  78. LYRUS: a machine learning model for predicting the pathogenicity of missense variants. Lai J, Yang J, Gamsiz Uzun ED, Rubenstein BM, Sarkar IN. Bioinform Adv 2 vbab045 (2022)
  79. Multi-dimensional computational pipeline for large-scale deep screening of compound effect assessment: an in silico case study on ageing-related compounds. Gupta V, Crudu A, Matsuoka Y, Ghosh S, Rozot R, Marat X, Jäger S, Kitano H, Breton L. NPJ Syst Biol Appl 5 42 (2019)
  80. PTENpred: A Designer Protein Impact Predictor for PTEN-related Disorders. Johnston SB, Raines RT. J Comput Biol 23 969-975 (2016)
  81. Protective effect of Cordyceps sinensis against diabetic kidney disease through promoting proliferation and inhibiting apoptosis of renal proximal tubular cells. Zhang Y, Xu L, Lu Y, Zhang J, Yang M, Tian Y, Dong J, Liao L. BMC Complement Med Ther 23 109 (2023)
  82. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  83. Comparative Protein Structural Network Analysis Reveals C-Terminal Tail Phosphorylation Structural Communication Fingerprint in PTEN-Associated Mutations in Autism and Cancer. Smith IN, Dawson JE, Eng C. J Phys Chem B 127 634-647 (2023)
  84. Exploring targets and signaling pathways of paeonol involved in relieving inflammation based on modern technology. Qi JH, Dong FX, Wang XL. Mol Divers 26 1731-1742 (2022)
  85. Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Kaymakcalan H, Kaya İ, Cevher Binici N, Nikerel E, Özbaran B, Görkem Aksoy M, Erbilgin S, Özyurt G, Jahan N, Çelik D, Yararbaş K, Yalçınkaya L, Köse S, Durak S, Ercan-Sencicek AG. Mol Genet Genomic Med 9 e1739 (2021)
  86. The Role of C2 Domains in Two Different Phosphatases: PTEN and SHIP2. John LH, Naughton FB, Sansom MSP, Larsen AH. Membranes (Basel) 13 408 (2023)
  87. Discovering Potential Anti-Oral Squamous Cell Carcinoma Mechanisms from Kochiae Fructus Using Network-Based Pharmacology Analysis and Experimental Validation. Kim YS, Lee JC, Lee M, Oh HJ, An WG, Sung ES. Life (Basel) 13 1300 (2023)
  88. GC-MS profiling of Bacillus spp. metabolites with an in vitro biological activity assessment and computational analysis of their impact on epithelial glioblastoma cancer genes. Naveed M, Ishfaq H, Rehman SU, Javed A, Waseem M, Makhdoom SI, Aziz T, Alharbi M, Alshammari A, Alasmari AF. Front Chem 11 1287599 (2023)
  89. Identification of hub genes and potential inhibitory compounds in the process of liver transplantation through transcriptome sequencing. Duan C, Zhao X, Li X, Xie J, Si Y, Wang L, Wu D, Wang Y, Liu S, Wang Q, Zhuang R, Yin W, Li J. Mol Cell Probes 72 101936 (2023)
  90. In-silico study of small cell lung cancer based on protein structure and function: A new approach to mimic biological system. Sood N, Chaudhary S, Pardeshi T, Mujawar S, Deshmukh KB, Sheikh SA, Sharma P. J Adv Pharm Technol Res 6 125-129 (2015)
  91. Network Pharmacology and Experimental Validation of the Anti-Inflammatory Effect of Tingli Dazao Xiefei Decoction in Acute Lung Injury Treatment. Zhang C, Li X, Gao D, Zhu H, Wang S, Tan B, Yang A. J Inflamm Res 16 6195-6209 (2023)
  92. Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy. Zhao J, Liu H, Xia M, Chen Q, Wan L, Leng B, Tang C, Chen G, Liu Y, Zhang L, Liu H. Drug Des Devel Ther 17 887-900 (2023)
  93. Neurodevelopmental disorders and cancer networks share pathways, but differ in mechanisms, signaling strength, and outcome. Yavuz BR, Arici MK, Demirel HC, Tsai CJ, Jang H, Nussinov R, Tuncbag N. NPJ Genom Med 8 37 (2023)
  94. Predicting Oncogenic Missense Mutations. Lei X, Wang B, Perez-Rathke A, Tian W, Chou CY, Tseng YY, Liang J. IEEE EMBS Int Conf Biomed Health Inform 2019 (2019)
  95. The Essential Oil from Oliveria decumbens Vent. (Apiaceae) as Inhibitor of Breast Cancer Cell (MCF-7) Growth. Shariatzadeh M, Karami A, Moghadam A, Lotfi M, Maggi F, Ebrahimie E. Pharmaceuticals (Basel) 16 59 (2022)


Reviews citing this publication (184)

  1. The functions and regulation of the PTEN tumour suppressor. Song MS, Salmena L, Pandolfi PP. Nat Rev Mol Cell Biol 13 283-296 (2012)
  2. Synthesis and function of 3-phosphorylated inositol lipids. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. Annu Rev Biochem 70 535-602 (2001)
  3. Phosphoinositides: tiny lipids with giant impact on cell regulation. Balla T. Physiol Rev 93 1019-1137 (2013)
  4. The multiple roles of PTEN in tumor suppression. Di Cristofano A, Pandolfi PP. Cell 100 387-390 (2000)
  5. PTEN and the PI3-kinase pathway in cancer. Chalhoub N, Baker SJ. Annu Rev Pathol 4 127-150 (2009)
  6. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Hollander MC, Blumenthal GM, Dennis PA. Nat Rev Cancer 11 289-301 (2011)
  7. PTEN: one gene, many syndromes. Eng C. Hum Mutat 22 183-198 (2003)
  8. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA. Curr Opin Cell Biol 17 183-189 (2005)
  9. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Polivka J, Janku F. Pharmacol Ther 142 164-175 (2014)
  10. PTEN: life as a tumor suppressor. Simpson L, Parsons R. Exp Cell Res 264 29-41 (2001)
  11. Cell signaling in space and time: where proteins come together and when they're apart. Scott JD, Pawson T. Science 326 1220-1224 (2009)
  12. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Chong ZZ, Li F, Maiese K. Prog Neurobiol 75 207-246 (2005)
  13. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Lee YR, Chen M, Pandolfi PP. Nat Rev Mol Cell Biol 19 547-562 (2018)
  14. Membrane-protein interactions in cell signaling and membrane trafficking. Cho W, Stahelin RV. Annu Rev Biophys Biomol Struct 34 119-151 (2005)
  15. Accessory factors in clathrin-dependent synaptic vesicle endocytosis. Slepnev VI, De Camilli P. Nat Rev Neurosci 1 161-172 (2000)
  16. PTEN and myotubularin: novel phosphoinositide phosphatases. Maehama T, Taylor GS, Dixon JE. Annu Rev Biochem 70 247-279 (2001)
  17. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Jeffrey KL, Camps M, Rommel C, Mackay CR. Nat Rev Drug Discov 6 391-403 (2007)
  18. PTEN. Worby CA, Dixon JE. Annu Rev Biochem 83 641-669 (2014)
  19. PTEN function: how normal cells control it and tumour cells lose it. Leslie NR, Downes CP. Biochem J 382 1-11 (2004)
  20. PTEN signaling pathways in melanoma. Wu H, Goel V, Haluska FG. Oncogene 22 3113-3122 (2003)
  21. Protean PTEN: form and function. Waite KA, Eng C. Am J Hum Genet 70 829-844 (2002)
  22. PTEN: The down side of PI 3-kinase signalling. Leslie NR, Downes CP. Cell Signal 14 285-295 (2002)
  23. Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction. Tonks NK. FEBS J 280 346-378 (2013)
  24. PTEN: a new guardian of the genome. Yin Y, Shen WH. Oncogene 27 5443-5453 (2008)
  25. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. Masson GR, Burke JE, Ahn NG, Anand GS, Borchers C, Brier S, Bou-Assaf GM, Engen JR, Englander SW, Faber J, Garlish R, Griffin PR, Gross ML, Guttman M, Hamuro Y, Heck AJR, Houde D, Iacob RE, Jørgensen TJD, Kaltashov IA, Klinman JP, Konermann L, Man P, Mayne L, Pascal BD, Reichmann D, Skehel M, Snijder J, Strutzenberg TS, Underbakke ES, Wagner C, Wales TE, Walters BT, Weis DD, Wilson DJ, Wintrode PL, Zhang Z, Zheng J, Schriemer DC, Rand KD. Nat Methods 16 595-602 (2019)
  26. PTEN: Multiple Functions in Human Malignant Tumors. Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L. Front Oncol 5 24 (2015)
  27. PTEN: Tumor Suppressor and Metabolic Regulator. Chen CY, Chen J, He L, Stiles BL. Front Endocrinol (Lausanne) 9 338 (2018)
  28. Phosphoinositides, key molecules for regulation of actin cytoskeletal organization and membrane traffic from the plasma membrane. Takenawa T, Itoh T. Biochim Biophys Acta 1533 190-206 (2001)
  29. Functions and mechanisms of redox regulation of cysteine-based phosphatases. Salmeen A, Barford D. Antioxid Redox Signal 7 560-577 (2005)
  30. PTEN function in normal and neoplastic growth. Chow LM, Baker SJ. Cancer Lett 241 184-196 (2006)
  31. Regulation of protein tyrosine phosphatases by reversible oxidation. Ostman A, Frijhoff J, Sandin A, Böhmer FD. J Biochem 150 345-356 (2011)
  32. PTENless means more. Stiles B, Groszer M, Wang S, Jiao J, Wu H. Dev Biol 273 175-184 (2004)
  33. PTEN function: the long and the short of it. Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. Trends Biochem Sci 39 183-190 (2014)
  34. Myocardial AKT: the omnipresent nexus. Sussman MA, Völkers M, Fischer K, Bailey B, Cottage CT, Din S, Gude N, Avitabile D, Alvarez R, Sundararaman B, Quijada P, Mason M, Konstandin MH, Malhowski A, Cheng Z, Khan M, McGregor M. Physiol Rev 91 1023-1070 (2011)
  35. Mammalian phosphoinositide kinases and phosphatases. Sasaki T, Takasuga S, Sasaki J, Kofuji S, Eguchi S, Yamazaki M, Suzuki A. Prog Lipid Res 48 307-343 (2009)
  36. Understanding PTEN regulation: PIP2, polarity and protein stability. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Oncogene 27 5464-5476 (2008)
  37. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Chong ZZ, Li F, Maiese K. Histol Histopathol 20 299-315 (2005)
  38. Human cancer, PTEN and the PI-3 kinase pathway. Parsons R. Semin Cell Dev Biol 15 171-176 (2004)
  39. Regulation of the PTEN phosphatase. Gericke A, Munson M, Ross AH. Gene 374 1-9 (2006)
  40. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. Mol Cancer 17 37 (2018)
  41. Redox regulation of PTEN and protein tyrosine phosphatases in H(2)O(2) mediated cell signaling. Cho SH, Lee CH, Ahn Y, Kim H, Kim H, Ahn CY, Yang KS, Lee SR. FEBS Lett 560 7-13 (2004)
  42. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Wishart MJ, Dixon JE. Trends Cell Biol 12 579-585 (2002)
  43. PTEN and PI3K/AKT in non-small-cell lung cancer. Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, Faus-Dáder MJ, Calleja-Hernández MÁ. Pharmacogenomics 16 1843-1862 (2015)
  44. Pten signaling in gliomas. Knobbe CB, Merlo A, Reifenberger G. Neuro Oncol 4 196-211 (2002)
  45. Targeting proteins with metal complexes. Meggers E. Chem Commun (Camb) 1001-1010 (2009)
  46. Non-genomic loss of PTEN function in cancer: not in my genes. Leslie NR, Foti M. Trends Pharmacol Sci 32 131-140 (2011)
  47. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Madhunapantula SV, Robertson GP. Pigment Cell Melanoma Res 22 400-419 (2009)
  48. Membrane recognition and targeting by lipid-binding domains. DiNitto JP, Cronin TC, Lambright DG. Sci STKE 2003 re16 (2003)
  49. Molecular underpinning of B-cell anergy. Yarkoni Y, Getahun A, Cambier JC. Immunol Rev 237 249-263 (2010)
  50. Sac phosphatase domain proteins. Hughes WE, Cooke FT, Parker PJ. Biochem J 350 Pt 2 337-352 (2000)
  51. Genetic alterations of PTEN in human melanoma. Aguissa-Touré AH, Li G. Cell Mol Life Sci 69 1475-1491 (2012)
  52. Molecular mechanisms of the PRL phosphatases. Rios P, Li X, Köhn M. FEBS J 280 505-524 (2013)
  53. The molecular machinery of neurotransmitter release (Nobel lecture). Südhof TC. Angew Chem Int Ed Engl 53 12696-12717 (2014)
  54. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Orloff MS, Eng C. Oncogene 27 5387-5397 (2008)
  55. Phosphoinositide phosphatases in cell biology and disease. Liu Y, Bankaitis VA. Prog Lipid Res 49 201-217 (2010)
  56. Phosphoinositide signaling; from affinity probes to pharmaceutical targets. Prestwich GD. Chem Biol 11 619-637 (2004)
  57. Post-translational regulation of PTEN. Wang X, Jiang X. Oncogene 27 5454-5463 (2008)
  58. Focus on PTEN Regulation. Bermúdez Brito M, Goulielmaki E, Papakonstanti EA. Front Oncol 5 166 (2015)
  59. The Role of mTOR Signaling as a Therapeutic Target in Cancer. Popova NV, Jücker M. Int J Mol Sci 22 1743 (2021)
  60. Class reunion: PTEN joins the nuclear crew. Lian Z, Di Cristofano A. Oncogene 24 7394-7400 (2005)
  61. PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, Milella M, Ciuffreda L. Cancers (Basel) 11 E435 (2019)
  62. Emerging role of PTEN loss in evasion of the immune response to tumours. Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Br J Cancer 122 1732-1743 (2020)
  63. Functions and Regulation of the PTEN Gene in Colorectal Cancer. Molinari F, Frattini M. Front Oncol 3 326 (2013)
  64. Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. Pulido R, Hooft van Huijsduijnen R. FEBS J 275 848-866 (2008)
  65. Lafora disease: insights into neurodegeneration from plant metabolism. Gentry MS, Dixon JE, Worby CA. Trends Biochem Sci 34 628-639 (2009)
  66. PTEN function in mammalian cell size regulation. Backman S, Stambolic V, Mak T. Curr Opin Neurobiol 12 516-522 (2002)
  67. Portrait of PTEN: messages from mutant mice. Suzuki A, Nakano T, Mak TW, Sasaki T. Cancer Sci 99 209-213 (2008)
  68. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking. Mellor P, Furber LA, Nyarko JN, Anderson DH. Biochem J 441 23-37 (2012)
  69. PTEN: tumour suppressor, multifunctional growth regulator and more. Goberdhan DC, Wilson C. Hum Mol Genet 12 Spec No 2 R239-48 (2003)
  70. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Madhunapantula SV, Mosca PJ, Robertson GP. Cancer Biol Ther 12 1032-1049 (2011)
  71. Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders. Kreis P, Leondaritis G, Lieberam I, Eickholt BJ. Front Mol Neurosci 7 23 (2014)
  72. Changing venues for tumour suppression: balancing destruction and localization by monoubiquitylation. Salmena L, Pandolfi PP. Nat Rev Cancer 7 409-413 (2007)
  73. Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder. Tilot AK, Frazier TW, Eng C. Neurotherapeutics 12 609-619 (2015)
  74. Heparanase and the hallmarks of cancer. Jayatilleke KM, Hulett MD. J Transl Med 18 453 (2020)
  75. Regulation of T-cell responses by PTEN. Buckler JL, Liu X, Turka LA. Immunol Rev 224 239-248 (2008)
  76. Voltage-sensing phosphatase: its molecular relationship with PTEN. Okamura Y, Dixon JE. Physiology (Bethesda) 26 6-13 (2011)
  77. Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock. Li Y, Alam HB. J Biomed Biotechnol 2011 523481 (2011)
  78. Kinases, tails and more: regulation of PTEN function by phosphorylation. Fragoso R, Barata JT. Methods 77-78 75-81 (2015)
  79. Redox toxicology of environmental chemicals causing oxidative stress. Zheng F, Gonçalves FM, Abiko Y, Li H, Kumagai Y, Aschner M. Redox Biol 34 101475 (2020)
  80. The functions of tumor suppressor PTEN in innate and adaptive immunity. Chen L, Guo D. Cell Mol Immunol 14 581-589 (2017)
  81. Body size regulation and insulin-like growth factor signaling. Hyun S. Cell Mol Life Sci 70 2351-2365 (2013)
  82. Genes and pathways driving glioblastomas in humans and murine disease models. Merlo A. Neurosurg Rev 26 145-158 (2003)
  83. PTEN: a default gate-keeping tumor suppressor with a versatile tail. Wang X, Jiang X. Cell Res 18 807-816 (2008)
  84. Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. Xu W, Yang Z, Zhou SF, Lu N. Drug Des Devel Ther 8 1745-1751 (2014)
  85. Study of PTEN subcellular localization. Bononi A, Pinton P. Methods 77-78 92-103 (2015)
  86. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Wang X, Huang H, Young KH. Aging (Albany NY) 7 1032-1049 (2015)
  87. Zooming in on disordered systems: neutron reflection studies of proteins associated with fluid membranes. Heinrich F, Lösche M. Biochim Biophys Acta 1838 2341-2349 (2014)
  88. The mechanism of action of the tumour suppressor gene PTEN. Hlobilková A, Knillová J, Bártek J, Lukás J, Kolár Z. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147 19-25 (2003)
  89. PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A. Cancers (Basel) 11 E1318 (2019)
  90. 65 YEARS OF THE DOUBLE HELIX: One gene, many endocrine and metabolic syndromes: PTEN-opathies and precision medicine. Yehia L, Eng C. Endocr Relat Cancer 25 T121-T140 (2018)
  91. PTEN Inhibition in Human Disease Therapy. Pulido R. Molecules 23 E285 (2018)
  92. PTEN and myotubularin phosphoinositide phosphatases: bringing bioinformatics to the lab bench. Wishart MJ, Taylor GS, Slama JT, Dixon JE. Curr Opin Cell Biol 13 172-181 (2001)
  93. PTEN: a yin-yang master regulator protein in health and disease. Pulido R. Methods 77-78 3-10 (2015)
  94. Lipid phosphatases in the regulation of T cell activation: living up to their PTEN-tial. Seminario MC, Wange RL. Immunol Rev 192 80-97 (2003)
  95. PtdIns(4,5)P2-mediated cell signaling: emerging principles and PTEN as a paradigm for regulatory mechanism. Gericke A, Leslie NR, Lösche M, Ross AH. Adv Exp Med Biol 991 85-104 (2013)
  96. The significance of PTEN's protein phosphatase activity. Leslie NR, Maccario H, Spinelli L, Davidson L. Adv Enzyme Regul 49 190-196 (2009)
  97. Biodiversity of voltage sensor domain proteins. Okamura Y. Pflugers Arch 454 361-371 (2007)
  98. PI(3,4)P2 Signaling in Cancer and Metabolism. Gozzelino L, De Santis MC, Gulluni F, Hirsch E, Martini M. Front Oncol 10 360 (2020)
  99. Phosphoglucan phosphatase function sheds light on starch degradation. Silver DM, Kötting O, Moorhead GB. Trends Plant Sci 19 471-478 (2014)
  100. Regulation and modulation of PTEN activity. Naderali E, Khaki AA, Rad JS, Ali-Hemmati A, Rahmati M, Charoudeh HN. Mol Biol Rep 45 2869-2881 (2018)
  101. Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. Cheng F, Liang H, Butte AJ, Eng C, Nussinov R. Pharmacol Rev 71 1-19 (2019)
  102. Structural Mechanisms of PTEN Regulation. Masson GR, Williams RL. Cold Spring Harb Perspect Med 10 a036152 (2020)
  103. In vitro models of axon regeneration. Al-Ali H, Beckerman SR, Bixby JL, Lemmon VP. Exp Neurol 287 423-434 (2017)
  104. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol. Ngeow J, Eng C. Methods 77-78 11-19 (2015)
  105. Redox regulation of the insulin signalling pathway. Lennicke C, Cochemé HM. Redox Biol 42 101964 (2021)
  106. Cell Polarity in Cerebral Cortex Development-Cellular Architecture Shaped by Biochemical Networks. Hansen AH, Duellberg C, Mieck C, Loose M, Hippenmeyer S. Front Cell Neurosci 11 176 (2017)
  107. Regulation of PTEN expression by noncoding RNAs. Li W, Zhang T, Guo L, Huang L. J Exp Clin Cancer Res 37 223 (2018)
  108. PTEN and melanomagenesis. Conde-Perez A, Larue L. Future Oncol 8 1109-1120 (2012)
  109. Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast. Cid VJ, Rodríguez-Escudero I, Andrés-Pons A, Romá-Mateo C, Gil A, den Hertog J, Molina M, Pulido R. Oncogene 27 5431-5442 (2008)
  110. PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations. Kar S, Samii A, Bertalanffy H. Neurosurg Rev 38 229-36; discussion 236-7 (2015)
  111. Phosphatidylinositol Kinases and Phosphatases in Entamoeba histolytica. Nakada-Tsukui K, Watanabe N, Maehama T, Nozaki T. Front Cell Infect Microbiol 9 150 (2019)
  112. Voltage-Sensing Phosphatases: Biophysics, Physiology, and Molecular Engineering. Okamura Y, Kawanabe A, Kawai T. Physiol Rev 98 2097-2131 (2018)
  113. Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes. Parsons R. Cold Spring Harb Perspect Med 10 a036129 (2020)
  114. Oncogenic PTEN functions and models in T-cell malignancies. Tesio M, Trinquand A, Macintyre E, Asnafi V. Oncogene 35 3887-3896 (2016)
  115. PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer. Csolle MP, Ooms LM, Papa A, Mitchell CA. Int J Mol Sci 21 E9189 (2020)
  116. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. Khamis ZI, Iczkowski KA, Sang QX. Med Res Rev 32 1026-1077 (2012)
  117. Apolipoprotein E4, Gender, Body Mass Index, Inflammation, Insulin Resistance, and Air Pollution Interactions: Recipe for Alzheimer's Disease Development in Mexico City Young Females. Calderón-Garcidueñas L, de la Monte SM. J Alzheimers Dis 58 613-630 (2017)
  118. The Role of PTEN in Neurodevelopment. Skelton PD, Stan RV, Luikart BW. Mol Neuropsychiatry 5 60-71 (2020)
  119. Conservation of the PTEN catalytic motif in the bacterial undecaprenyl pyrophosphate phosphatase, BacA/UppP. Bickford JS, Nick HS. Microbiology (Reading) 159 2444-2455 (2013)
  120. Floundering about at cell membranes: a structural view of phospholipid signaling. Hurley JH, Tsujishita Y, Pearson MA. Curr Opin Struct Biol 10 737-743 (2000)
  121. Posttranslational Regulation and Conformational Plasticity of PTEN. Kotelevets L, Trifault B, Chastre E, Scott MGH. Cold Spring Harb Perspect Med 10 a036095 (2020)
  122. Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Bielecka ZF, Czarnecka AM, Szczylik C. Front Oncol 4 194 (2014)
  123. Redox Regulation of PTEN by Peroxiredoxins. Nguyen Huu T, Park J, Zhang Y, Park I, Yoon HJ, Woo HA, Lee SR. Antioxidants (Basel) 10 302 (2021)
  124. CNS repair and axon regeneration: Using genetic variation to determine mechanisms. Tedeschi A, Omura T, Costigan M. Exp Neurol 287 409-422 (2017)
  125. Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders. Rana A, Goyal N, Ahlawat A, Jamwal S, Reddy BV, Sharma S. Perfusion 30 94-105 (2015)
  126. Tumour-suppressor function in the nervous system. Baker SJ, McKinnon PJ. Nat Rev Cancer 4 184-196 (2004)
  127. Targeting protein kinase-b3 (akt3) signaling in melanoma. Madhunapantula SV, Robertson GP. Expert Opin Ther Targets 21 273-290 (2017)
  128. Multifaceted Regulation of PTEN Subcellular Distributions and Biological Functions. Liu T, Wang Y, Wang Y, Chan AM. Cancers (Basel) 11 E1247 (2019)
  129. New insights in the activity of voltage sensitive phosphatases. Villalba-Galea CA. Cell Signal 24 1541-1547 (2012)
  130. Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition. Nussinov R, Zhang M, Tsai CJ, Jang H. Mol Cancer Res 19 543-548 (2021)
  131. Phospholipids of the Plasma Membrane - Regulators or Consequence of Cell Polarity? Krahn MP. Front Cell Dev Biol 8 277 (2020)
  132. Role of Ubiquitination in PTEN Cellular Homeostasis and Its Implications in GB Drug Resistance. Xia Q, Ali S, Liu L, Li Y, Liu X, Zhang L, Dong L. Front Oncol 10 1569 (2020)
  133. Structure and catalytic mechanism of human protein tyrosine phosphatome. Kim SJ, Ryu SE. BMB Rep 45 693-699 (2012)
  134. The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review. Lu YM, Cheng F, Teng LS. Sci Rep 6 32723 (2016)
  135. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs. Nussinov R, Zhang M, Maloney R, Liu Y, Tsai CJ, Jang H. J Mol Biol 434 167569 (2022)
  136. Phosphatase and tensin homologue: a therapeutic target for SMA. Godena VK, Ning K. Signal Transduct Target Ther 2 17038 (2017)
  137. The Long and the Short of PTEN in the Regulation of Mitophagy. Wang L, Lu G, Shen HM. Front Cell Dev Biol 8 299 (2020)
  138. A Drosophila-centric view of protein tyrosine phosphatases. Hatzihristidis T, Desai N, Hutchins AP, Meng TC, Tremblay ML, Miranda-Saavedra D. FEBS Lett 589 951-966 (2015)
  139. Impact of p85α Alterations in Cancer. Marshall JDS, Whitecross DE, Mellor P, Anderson DH. Biomolecules 9 E29 (2019)
  140. Neural regeneration: lessons from regenerating and non-regenerating systems. Ferreira LM, Floriddia EM, Quadrato G, Di Giovanni S. Mol Neurobiol 46 227-241 (2012)
  141. Role of PTEN-less in cardiac injury, hypertrophy and regeneration. Liang T, Gao F, Chen J. Cell Regen 10 25 (2021)
  142. Voltage sensor of ion channels and enzymes. Gonzalez C, Contreras GF, Peyser A, Larsson P, Neely A, Latorre R. Biophys Rev 4 1-15 (2012)
  143. Dual-Specific Protein and Lipid Phosphatase PTEN and Its Biological Functions. Tu T, Chen J, Chen L, Stiles BL. Cold Spring Harb Perspect Med 10 a036301 (2020)
  144. Functions of mammalian SIRT4 in cellular metabolism and research progress in human cancer. Wang C, Liu Y, Zhu Y, Kong C. Oncol Lett 20 11 (2020)
  145. PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression. Liu A, Zhu Y, Chen W, Merlino G, Yu Y. Cancers (Basel) 14 3666 (2022)
  146. PTEN: a newly identified regulator of neuronal differentiation. Ross AH, Lachyankar MB, Recht LD. Neuroscientist 7 278-281 (2001)
  147. The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers. Wang Q, Wang J, Xiang H, Ding P, Wu T, Ji G. Am J Cancer Res 11 5833-5855 (2021)
  148. PTEN: Bridging Endocytosis and Signaling. Lee MF, Trotman LC. Cold Spring Harb Perspect Med 10 a036103 (2020)
  149. Redox control of enzymatic functions: The electronics of life's circuitry. Bonini MG, Consolaro MEL, Hart PC, Mao M, de Abreu ALP, Master AM. IUBMB Life 66 167-181 (2014)
  150. Analysis of intracellular PTEN signaling and secretion. Hodakoski C, Fine B, Hopkins B, Parsons R. Methods 77-78 164-171 (2015)
  151. Body size regulation by maturation steroid hormones: a Drosophila perspective. Hyun S. Front Zool 15 44 (2018)
  152. Phosphatase and Tensin Homologue: Novel Regulation by Developmental Signaling. Jerde TJ. J Signal Transduct 2015 282567 (2015)
  153. Molecular biology of lung cancer. Kaye FJ. Lung Cancer 34 Suppl 2 S35-41 (2001)
  154. PTEN in brain tumors. Haas-Kogan D, Stokoe D. Expert Rev Neurother 8 599-610 (2008)
  155. Recent advances in PTEN signalling axes in cancer. Chow JT, Salmena L. Fac Rev 9 31 (2020)
  156. The Roles of Signaling in Cytoskeletal Changes, Random Movement, Direction-Sensing and Polarization of Eukaryotic Cells. Cheng Y, Felix B, Othmer HG. Cells 9 E1437 (2020)
  157. Yeast-based methods to assess PTEN phosphoinositide phosphatase activity in vivo. Rodríguez-Escudero I, Fernández-Acero T, Bravo I, Leslie NR, Pulido R, Molina M, Cid VJ. Methods 77-78 172-179 (2015)
  158. Biochemistry and structure of phosphoinositide phosphatases. Kim YJ, Jahan N, Bahk YY. BMB Rep 46 1-8 (2013)
  159. Biophysical methods for the characterization of PTEN/lipid bilayer interactions. Harishchandra RK, Neumann BM, Gericke A, Ross AH. Methods 77-78 125-135 (2015)
  160. Electrifying phosphatases. Horn R. Sci STKE 2005 pe50 (2005)
  161. Membrane proteins: adapting to life at the interface. Hurley JH. Chem Biol 10 2-3 (2003)
  162. Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M. Mol Cell Oncol 1 e963447 (2014)
  163. PTEN, Longevity and Age-Related Diseases. Tait IS, Li Y, Lu J. Biomedicines 1 17-48 (2013)
  164. Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer. Dirican E, Akkiprik M. Tumour Biol 39 1010428317695529 (2017)
  165. Prostate cancer genomics. Li PE, Nelson PS. Curr Urol Rep 2 70-78 (2001)
  166. Protein tyrosine phosphatases in cardiac physiology and pathophysiology. Wade F, Belhaj K, Poizat C. Heart Fail Rev 23 261-272 (2018)
  167. Regulation of PTEN in neurons by myosin-based transport mechanisms. Kreis P, van Diepen MT, Eickholt BJ. Adv Enzyme Regul 50 119-124 (2010)
  168. Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches. Shanak S, Bassalat N, Barghash A, Kadan S, Ardah M, Zaid H. Evid Based Complement Alternat Med 2022 2832889 (2022)
  169. Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers. Langdon CG. Biomolecules 13 259 (2023)
  170. PTEN as a unique promising therapeutic target for occupational asthma. Kim SR, Lee YC. Immunopharmacol Immunotoxicol 30 793-814 (2008)
  171. Pseudogenes in gastric cancer pathogenesis: a review article. Emadi-Baygi M, Sedighi R, Nourbakhsh N, Nikpour P. Brief Funct Genomics 16 348-360 (2017)
  172. Pten function in zebrafish: anything but a fish story. Stumpf M, Choorapoikayil S, den Hertog J. Methods 77-78 191-196 (2015)
  173. The Role of PTEN-L in Modulating PINK1-Parkin-Mediated Mitophagy. Eldeeb MA, Esmaili M, Hassan M, Ragheb MA. Neurotox Res 40 1103-1114 (2022)
  174. Toward Systems Pathology for PTEN Diagnostics. Haddadi N, Travis G, Nassif NT, Simpson AM, Marsh DJ. Cold Spring Harb Perspect Med 10 a037127 (2020)
  175. Voltage-Gated T-Type Calcium Channel Modulation by Kinases and Phosphatases: The Old Ones, the New Ones, and the Missing Ones. Sharma A, Rahman G, Gorelik J, Bhargava A. Cells 12 461 (2023)
  176. Drosophila melanogaster diabetes models and its usage in the research of anti-diabetes management with traditional Chinese medicines. Miao Y, Chen R, Wang X, Zhang J, Tang W, Zhang Z, Liu Y, Xu Q. Front Med (Lausanne) 9 953490 (2022)
  177. Phosphatase and Tensin Homolog in Non-neoplastic Digestive Disease: More Than Just Tumor Suppressor. He T, Zhang X, Hao J, Ding S. Front Physiol 12 684529 (2021)
  178. The orchestrated signaling by PI3Kα and PTEN at the membrane interface. Kotzampasi DM, Premeti K, Papafotika A, Syropoulou V, Christoforidis S, Cournia Z, Leondaritis G. Comput Struct Biotechnol J 20 5607-5621 (2022)
  179. The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. II. Products of suppressor genes Rb and PTEN, CDKI, Fas. Knillová J, Kolár Z, Hlobilková A. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147 11-17 (2003)
  180. When PIP2 Meets p53: Nuclear Phosphoinositide Signaling in the DNA Damage Response. Wang YH, Sheetz MP. Front Cell Dev Biol 10 903994 (2022)
  181. X-ray crystallography and NMR as tools for the study of protein tyrosine phosphatases. Gulerez IE, Gehring K. Methods 65 175-183 (2014)
  182. Endothelial plasticity across PTEN and Hippo pathways: A complex hormetic rheostat modulated by extracellular vesicles. Orozco-García E, van Meurs DJ, Calderón JC, Narvaez-Sanchez R, Harmsen MC. Transl Oncol 31 101633 (2023)
  183. Glioblastomas on the move. Merlo A, Bettler B. Sci STKE 2004 pe18 (2004)
  184. Role of gut commensal bacteria in juvenile developmental growth of the host: insights from Drosophila studies. Yun HM, Hyun S. Anim Cells Syst (Seoul) 27 329-339 (2023)

Articles citing this publication (397)

  1. Tenets of PTEN tumor suppression. Salmena L, Carracedo A, Pandolfi PP. Cell 133 403-414 (2008)
  2. Reversible inactivation of the tumor suppressor PTEN by H2O2. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. J Biol Chem 277 20336-20342 (2002)
  3. Phosphorylation of the PTEN tail regulates protein stability and function. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Mol Cell Biol 20 5010-5018 (2000)
  4. Ubiquitination regulates PTEN nuclear import and tumor suppression. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP. Cell 128 141-156 (2007)
  5. Phosphoinositide phosphatase activity coupled to an intrinsic voltage sensor. Murata Y, Iwasaki H, Sasaki M, Inaba K, Okamura Y. Nature 435 1239-1243 (2005)
  6. Automated inference of molecular mechanisms of disease from amino acid substitutions. Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, Cooper DN, Mooney SD, Radivojac P. Bioinformatics 25 2744-2750 (2009)
  7. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Iijima M, Devreotes P. Cell 109 599-610 (2002)
  8. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG. Proc Natl Acad Sci U S A 101 16419-16424 (2004)
  9. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ. Mol Cell Biol 20 9138-9148 (2000)
  10. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Mol Cell Biol 20 8969-8982 (2000)
  11. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H. Cancer Cell 3 117-130 (2003)
  12. A biosynthetic pathway for anandamide. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim HY, Kunos G. Proc Natl Acad Sci U S A 103 13345-13350 (2006)
  13. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE. Proc Natl Acad Sci U S A 97 4233-4238 (2000)
  14. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Georgescu MM. Genes Cancer 1 1170-1177 (2010)
  15. Membrane-binding and activation mechanism of PTEN. Das S, Dixon JE, Cho W. Proc Natl Acad Sci U S A 100 7491-7496 (2003)
  16. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA. EMBO J 28 1505-1517 (2009)
  17. Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Taylor GS, Maehama T, Dixon JE. Proc Natl Acad Sci U S A 97 8910-8915 (2000)
  18. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, Zack JA, Geschwind DH, Liu X, Kornblum HI, Wu H. Proc Natl Acad Sci U S A 103 111-116 (2006)
  19. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. Proc Natl Acad Sci U S A 106 480-485 (2009)
  20. Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, Lunardi A, Webster K, Ng C, Newton RH, Knoblauch N, Guarnerio J, Ito K, Turka LA, Beck AH, Pinton P, Bronson RT, Wei W, Pandolfi PP. Cell 157 595-610 (2014)
  21. PTEN functions to 'prioritize' chemotactic cues and prevent 'distraction' in migrating neutrophils. Heit B, Robbins SM, Downey CM, Guan Z, Colarusso P, Miller BJ, Jirik FR, Kubes P. Nat Immunol 9 743-752 (2008)
  22. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. Gregorian C, Nakashima J, Le Belle J, Ohab J, Kim R, Liu A, Smith KB, Groszer M, Garcia AD, Sofroniew MV, Carmichael ST, Kornblum HI, Liu X, Wu H. J Neurosci 29 1874-1886 (2009)
  23. Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Blondeau F, Laporte J, Bodin S, Superti-Furga G, Payrastre B, Mandel JL. Hum Mol Genet 9 2223-2229 (2000)
  24. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. J Biol Chem 278 40057-40066 (2003)
  25. Bisperoxovanadium compounds are potent PTEN inhibitors. Schmid AC, Byrne RD, Vilar R, Woscholski R. FEBS Lett 566 35-38 (2004)
  26. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF, Dean NM, Bhanot S, Monia BP. Diabetes 51 1028-1034 (2002)
  27. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Buxbaum JD, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsäter H, Rastam M, Smith CJ, Silverman JM, Hollander E, Leboyer M, Gillberg C, Verloes A, Betancur C. Am J Med Genet B Neuropsychiatr Genet 144B 484-491 (2007)
  28. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, Mannoor K, Deepak J, Donahue JM, Stass SA, Xing L, Jiang F. Oncogene 33 1181-1189 (2014)
  29. PTEN controls tumor-induced angiogenesis. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. Proc Natl Acad Sci U S A 98 4622-4627 (2001)
  30. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. Mol Cell Biol 23 6139-6149 (2003)
  31. Electrostatic control of the membrane targeting of C2 domains. Murray D, Honig B. Mol Cell 9 145-154 (2002)
  32. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. EMBO J 25 910-920 (2006)
  33. Novel mechanism of PTEN regulation by its phosphatidylinositol 4,5-bisphosphate binding motif is critical for chemotaxis. Iijima M, Huang YE, Luo HR, Vazquez F, Devreotes PN. J Biol Chem 279 16606-16613 (2004)
  34. Protein kinases and phosphatases in the control of cell fate. Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, Giorgi C, Missiroli S, Poletti F, Rimessi A, Pinton P. Enzyme Res 2011 329098 (2011)
  35. PCAF modulates PTEN activity. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. J Biol Chem 281 26562-26568 (2006)
  36. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, Zhu C, Chen C, Liu X, Cheng J, Mustelin T, Feng GS, Chen G, Yu J. Nat Commun 3 911 (2012)
  37. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Lee YR, Chen M, Lee JD, Zhang J, Lin SY, Fu TM, Chen H, Ishikawa T, Chiang SY, Katon J, Zhang Y, Shulga YV, Bester AC, Fung J, Monteleone E, Wan L, Shen C, Hsu CH, Papa A, Clohessy JG, Teruya-Feldstein J, Jain S, Wu H, Matesic L, Chen RH, Wei W, Pandolfi PP. Science 364 eaau0159 (2019)
  38. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. Proc Natl Acad Sci U S A 103 3633-3638 (2006)
  39. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, de la Chapelle A, Aaltonen LA, Eng C. Am J Pathol 161 439-447 (2002)
  40. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Rodríguez-Escudero I, Oliver MD, Andrés-Pons A, Molina M, Cid VJ, Pulido R. Hum Mol Genet 20 4132-4142 (2011)
  41. Comprehensive assessment of cancer missense mutation clustering in protein structures. Kamburov A, Lawrence MS, Polak P, Leshchiner I, Lage K, Golub TR, Lander ES, Getz G. Proc Natl Acad Sci U S A 112 E5486-95 (2015)
  42. Deubiquitylation and stabilization of PTEN by USP13. Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, Wang M, Chen D, Sun Y, Hung MC, Chen J, Ma L. Nat Cell Biol 15 1486-1494 (2013)
  43. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Arch Biochem Biophys 429 123-133 (2004)
  44. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, Wu H, Hla T. Proc Natl Acad Sci U S A 102 4312-4317 (2005)
  45. PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Leslie NR, Yang X, Downes CP, Weijer CJ. Curr Biol 17 115-125 (2007)
  46. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Am J Pathol 176 2626-2637 (2010)
  47. E-Syts, a family of membranous Ca2+-sensor proteins with multiple C2 domains. Min SW, Chang WP, Südhof TC. Proc Natl Acad Sci U S A 104 3823-3828 (2007)
  48. A burst of auxilin recruitment determines the onset of clathrin-coated vesicle uncoating. Massol RH, Boll W, Griffin AM, Kirchhausen T. Proc Natl Acad Sci U S A 103 10265-10270 (2006)
  49. Letter The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. Tan WH, Baris HN, Burrows PE, Robson CD, Alomari AI, Mulliken JB, Fishman SJ, Irons MB. J Med Genet 44 594-602 (2007)
  50. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. Mol Cell Biol 33 3091-3098 (2013)
  51. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. Oncogene 31 1264-1274 (2012)
  52. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. Biochem J 379 301-307 (2004)
  53. 5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM, Moodie S, Stokoe D. Mol Cell Biol 20 6860-6871 (2000)
  54. TPIP: a novel phosphoinositide 3-phosphatase. Walker SM, Downes CP, Leslie NR. Biochem J 360 277-283 (2001)
  55. Subunit organization and functional transitions in Ci-VSP. Kohout SC, Ulbrich MH, Bell SC, Isacoff EY. Nat Struct Mol Biol 15 106-108 (2008)
  56. The structure of the cell cycle protein Cdc14 reveals a proline-directed protein phosphatase. Gray CH, Good VM, Tonks NK, Barford D. EMBO J 22 3524-3535 (2003)
  57. The C2 domain of the Rsp5 ubiquitin ligase binds membrane phosphoinositides and directs ubiquitination of endosomal cargo. Dunn R, Klos DA, Adler AS, Hicke L. J Cell Biol 165 135-144 (2004)
  58. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C, Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J, White KP. Cancer Cell 25 455-468 (2014)
  59. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Int J Cancer 118 1877-1883 (2006)
  60. Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway. Guo LT, Wang SQ, Su J, Xu LX, Ji ZY, Zhang RY, Zhao QW, Ma ZQ, Deng XY, Ma SP. J Neuroinflammation 16 95 (2019)
  61. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. Mol Cell Biol 28 3281-3289 (2008)
  62. Crystal structure of a phosphoinositide phosphatase, MTMR2: insights into myotubular myopathy and Charcot-Marie-Tooth syndrome. Begley MJ, Taylor GS, Kim SA, Veine DM, Dixon JE, Stuckey JA. Mol Cell 12 1391-1402 (2003)
  63. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Gil A, Andrés-Pons A, Fernández E, Valiente M, Torres J, Cervera J, Pulido R. Mol Biol Cell 17 4002-4013 (2006)
  64. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. Am J Pathol 159 359-367 (2001)
  65. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner. Song P, Wu Y, Xu J, Xie Z, Dong Y, Zhang M, Zou MH. Circulation 116 1585-1595 (2007)
  66. On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Numajiri N, Takasawa K, Nishiya T, Tanaka H, Ohno K, Hayakawa W, Asada M, Matsuda H, Azumi K, Kamata H, Nakamura T, Hara H, Minami M, Lipton SA, Uehara T. Proc Natl Acad Sci U S A 108 10349-10354 (2011)
  67. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, Chen H, Zhao LD, Zeng XF, Zhang FC, Tang FL, He W, Cao XT, Zhang X, Lipsky PE. Sci Transl Med 6 246ra99 (2014)
  68. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Davidson L, Maccario H, Perera NM, Yang X, Spinelli L, Tibarewal P, Glancy B, Gray A, Weijer CJ, Downes CP, Leslie NR. Oncogene 29 687-697 (2010)
  69. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, Jalaludin B, Segelov E. Oncogene 23 617-628 (2004)
  70. NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Kwak YD, Ma T, Diao S, Zhang X, Chen Y, Hsu J, Lipton SA, Masliah E, Xu H, Liao FF. Mol Neurodegener 5 49 (2010)
  71. Identification of novel families and classification of the C2 domain superfamily elucidate the origin and evolution of membrane targeting activities in eukaryotes. Zhang D, Aravind L. Gene 469 18-30 (2010)
  72. A tumor suppressor homolog, AtPTEN1, is essential for pollen development in Arabidopsis. Gupta R, Ting JT, Sokolov LN, Johnson SA, Luan S. Plant Cell 14 2495-2507 (2002)
  73. LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Mehenni H, Lin-Marq N, Buchet-Poyau K, Reymond A, Collart MA, Picard D, Antonarakis SE. Hum Mol Genet 14 2209-2219 (2005)
  74. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Am J Physiol Heart Circ Physiol 295 H1580-6 (2008)
  75. Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Yeon JE, Califano S, Xu J, Wands JR, De La Monte SM. Hepatology 38 703-714 (2003)
  76. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Proc Natl Acad Sci U S A 102 2703-2706 (2005)
  77. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Mol Cell Biol 25 6211-6224 (2005)
  78. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. Mahimainathan L, Choudhury GG. J Biol Chem 279 15258-15268 (2004)
  79. PTEN enters the nucleus by diffusion. Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH. J Cell Biochem 96 221-234 (2005)
  80. C2 domains of protein kinase C isoforms alpha, beta, and gamma: activation parameters and calcium stoichiometries of the membrane-bound state. Kohout SC, Corbalán-García S, Torrecillas A, Goméz-Fernandéz JC, Falke JJ. Biochemistry 41 11411-11424 (2002)
  81. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, Perera NM, Davidson L, Barton GJ, Leslie NR. Sci Signal 5 ra18 (2012)
  82. Increased membrane affinity of the C1 domain of protein kinase Cdelta compensates for the lack of involvement of its C2 domain in membrane recruitment. Giorgione JR, Lin JH, McCammon JA, Newton AC. J Biol Chem 281 1660-1669 (2006)
  83. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R, Georgescu MM, Nanus DM. Cancer Cell 5 67-78 (2004)
  84. Mechanistic insights into the anchorage of the contractile ring by anillin and Mid1. Sun L, Guan R, Lee IJ, Liu Y, Chen M, Wang J, Wu JQ, Chen Z. Dev Cell 33 413-426 (2015)
  85. PTEN is a protein tyrosine phosphatase for IRS1. Shi Y, Wang J, Chandarlapaty S, Cross J, Thompson C, Rosen N, Jiang X. Nat Struct Mol Biol 21 522-527 (2014)
  86. Crystal structure of the yeast Sac1: implications for its phosphoinositide phosphatase function. Manford A, Xia T, Saxena AK, Stefan C, Hu F, Emr SD, Mao Y. EMBO J 29 1489-1498 (2010)
  87. Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. McConnachie G, Pass I, Walker SM, Downes CP. Biochem J 371 947-955 (2003)
  88. The type Ialpha inositol polyphosphate 4-phosphatase generates and terminates phosphoinositide 3-kinase signals on endosomes and the plasma membrane. Ivetac I, Munday AD, Kisseleva MV, Zhang XM, Luff S, Tiganis T, Whisstock JC, Rowe T, Majerus PW, Mitchell CA. Mol Biol Cell 16 2218-2233 (2005)
  89. Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Müller V, Westphal M, Pantel K. Breast Cancer Res 14 R49 (2012)
  90. Structural basis for substrate recognition by a unique Legionella phosphoinositide phosphatase. Hsu F, Zhu W, Brennan L, Tao L, Luo ZQ, Mao Y. Proc Natl Acad Sci U S A 109 13567-13572 (2012)
  91. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB. Proc Natl Acad Sci U S A 109 14164-14169 (2012)
  92. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. He L, Ingram A, Rybak AP, Tang D. J Clin Invest 120 2094-2108 (2010)
  93. Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, Ekiel I. J Biol Chem 279 11882-11889 (2004)
  94. miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P, Yu Z. J Exp Clin Cancer Res 33 67 (2014)
  95. PTEN and p53: who will get the upper hand? Trotman LC, Pandolfi PP. Cancer Cell 3 97-99 (2003)
  96. Phosphorylation-mediated PTEN conformational closure and deactivation revealed with protein semisynthesis. Bolduc D, Rahdar M, Tu-Sekine B, Sivakumaren SC, Raben D, Amzel LM, Devreotes P, Gabelli SB, Cole P. Elife 2 e00691 (2013)
  97. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Keyes KT, Xu J, Long B, Zhang C, Hu Z, Ye Y. Am J Physiol Heart Circ Physiol 298 H1198-208 (2010)
  98. Functional analysis of the protein phosphatase activity of PTEN. Zhang XC, Piccini A, Myers MP, Van Aelst L, Tonks NK. Biochem J 444 457-464 (2012)
  99. PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor suppressor lipid phosphatase. Wu Y, Dowbenko D, Pisabarro MT, Dillard-Telm L, Koeppen H, Lasky LA. J Biol Chem 276 21745-21753 (2001)
  100. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Yan X, Fraser M, Qiu Q, Tsang BK. Gynecol Oncol 102 348-355 (2006)
  101. Structure and mechanism of the RNA triphosphatase component of mammalian mRNA capping enzyme. Changela A, Ho CK, Martins A, Shuman S, Mondragón A. EMBO J 20 2575-2586 (2001)
  102. Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. Shin OH, Han W, Wang Y, Südhof TC. J Biol Chem 280 1641-1651 (2005)
  103. Protein tyrosine phosphatase RQ is a phosphatidylinositol phosphatase that can regulate cell survival and proliferation. Oganesian A, Poot M, Daum G, Coats SA, Wright MB, Seifert RA, Bowen-Pope DF. Proc Natl Acad Sci U S A 100 7563-7568 (2003)
  104. A novel phosphatidylinositol(3,4,5)P3 pathway in fission yeast. Mitra P, Zhang Y, Rameh LE, Ivshina MP, McCollum D, Nunnari JJ, Hendricks GM, Kerr ML, Field SJ, Cantley LC, Ross AH. J Cell Biol 166 205-211 (2004)
  105. Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel. Mester JL, Ghosh R, Pesaran T, Huether R, Karam R, Hruska KS, Costa HA, Lachlan K, Ngeow J, Barnholtz-Sloan J, Sesock K, Hernandez F, Zhang L, Milko L, Plon SE, Hegde M, Eng C. Hum Mutat 39 1581-1592 (2018)
  106. Class II formin targeting to the cell cortex by binding PI(3,5)P(2) is essential for polarized growth. van Gisbergen PA, Li M, Wu SZ, Bezanilla M. J Cell Biol 198 235-250 (2012)
  107. A PTEN-like phosphatase with a novel substrate specificity. Pagliarini DJ, Worby CA, Dixon JE. J Biol Chem 279 38590-38596 (2004)
  108. The TPTE gene family: cellular expression, subcellular localization and alternative splicing. Tapparel C, Reymond A, Girardet C, Guillou L, Lyle R, Lamon C, Hutter P, Antonarakis SE. Gene 323 189-199 (2003)
  109. The TriTryp phosphatome: analysis of the protein phosphatase catalytic domains. Brenchley R, Tariq H, McElhinney H, Szöor B, Huxley-Jones J, Stevens R, Matthews K, Tabernero L. BMC Genomics 8 434 (2007)
  110. Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. Song P, Xie Z, Wu Y, Xu J, Dong Y, Zou MH. J Biol Chem 283 12446-12455 (2008)
  111. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Oncogene 21 2357-2364 (2002)
  112. PTEN functions by recruitment to cytoplasmic vesicles. Naguib A, Bencze G, Cho H, Zheng W, Tocilj A, Elkayam E, Faehnle CR, Jaber N, Pratt CP, Chen M, Zong WX, Marks MS, Joshua-Tor L, Pappin DJ, Trotman LC. Mol Cell 58 255-268 (2015)
  113. PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Tian T, Nan KJ, Wang SH, Liang X, Lu CX, Guo H, Wang WJ, Ruan ZP. Carcinogenesis 31 1211-1219 (2010)
  114. PTEN-mediated Akt/β-catenin/Foxo1 signaling regulates innate immune responses in mouse liver ischemia/reperfusion injury. Kamo N, Ke B, Busuttil RW, Kupiec-Weglinski JW. Hepatology 57 289-298 (2013)
  115. Phosphorylation keeps PTEN phosphatase closed for business. Ross AH, Gericke A. Proc Natl Acad Sci U S A 106 1297-1298 (2009)
  116. Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium. Kim JW, Kang KH, Burrola P, Mak TW, Lemke G. Genes Dev 22 3147-3157 (2008)
  117. Characterisation of the PTEN inhibitor VO-OHpic. Mak LH, Vilar R, Woscholski R. J Chem Biol 3 157-163 (2010)
  118. Coupling between the voltage-sensing and phosphatase domains of Ci-VSP. Villalba-Galea CA, Miceli F, Taglialatela M, Bezanilla F. J Gen Physiol 134 5-14 (2009)
  119. Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. Bodian DL, McCutcheon JN, Kothiyal P, Huddleston KC, Iyer RK, Vockley JG, Niederhuber JE. PLoS One 9 e94554 (2014)
  120. MptpB, a virulence factor from Mycobacterium tuberculosis, exhibits triple-specificity phosphatase activity. Beresford N, Patel S, Armstrong J, Szöor B, Fordham-Skelton AP, Tabernero L. Biochem J 406 13-18 (2007)
  121. A new role for PTEN in regulating transient receptor potential canonical channel 6-mediated Ca2+ entry, endothelial permeability, and angiogenesis. Kini V, Chavez A, Mehta D. J Biol Chem 285 33082-33091 (2010)
  122. Bacillus subtilis arsenate reductase is structurally and functionally similar to low molecular weight protein tyrosine phosphatases. Bennett MS, Guan Z, Laurberg M, Su XD. Proc Natl Acad Sci U S A 98 13577-13582 (2001)
  123. Dormant Intestinal Stem Cells Are Regulated by PTEN and Nutritional Status. Richmond CA, Shah MS, Deary LT, Trotier DC, Thomas H, Ambruzs DM, Jiang L, Whiles BB, Rickner HD, Montgomery RK, Tovaglieri A, Carlone DL, Breault DT. Cell Rep 13 2403-2411 (2015)
  124. Identification and structural characterization of a Legionella phosphoinositide phosphatase. Toulabi L, Wu X, Cheng Y, Mao Y. J Biol Chem 288 24518-24527 (2013)
  125. Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation. Zhao M, Schmitz AA, Qin Y, Di Cristofano A, Pandolfi PP, Van Aelst L. J Exp Med 194 265-274 (2001)
  126. Intrinsic disorder in PTEN and its interactome confers structural plasticity and functional versatility. Malaney P, Pathak RR, Xue B, Uversky VN, Davé V. Sci Rep 3 2035 (2013)
  127. AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Rader J, Grigsby PW, Schwarz JK. PLoS One 9 e92948 (2014)
  128. PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. Phadngam S, Castiglioni A, Ferraresi A, Morani F, Follo C, Isidoro C. Oncotarget 7 84999-85020 (2016)
  129. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Leslie NR, Gray A, Pass I, Orchiston EA, Downes CP. Biochem J 346 Pt 3 827-833 (2000)
  130. Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Siddall HK, Warrell CE, Yellon DM, Mocanu MM. Basic Res Cardiol 103 560-568 (2008)
  131. Planarian PTEN homologs regulate stem cells and regeneration through TOR signaling. Oviedo NJ, Pearson BJ, Levin M, Sánchez Alvarado A. Dis Model Mech 1 131-43; discussion 141 (2008)
  132. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao MS, Mak T, Fyles A, Liu FF. Int J Cancer 104 195-203 (2003)
  133. Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Molina JR, Morales FC, Hayashi Y, Aldape KD, Georgescu MM. Cancer Res 70 6697-6703 (2010)
  134. Structures of Selenomonas ruminantium phytase in complex with persulfated phytate: DSP phytase fold and mechanism for sequential substrate hydrolysis. Chu HM, Guo RT, Lin TW, Chou CC, Shr HL, Lai HL, Tang TY, Cheng KJ, Selinger BL, Wang AH. Structure 12 2015-2024 (2004)
  135. Membrane association of the PTEN tumor suppressor: molecular details of the protein-membrane complex from SPR binding studies and neutron reflection. Shenoy S, Shekhar P, Heinrich F, Daou MC, Gericke A, Ross AH, Lösche M. PLoS One 7 e32591 (2012)
  136. The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity. Masson GR, Perisic O, Burke JE, Williams RL. Biochem J 473 135-144 (2016)
  137. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, Kurama T, Shimokawa T, Aramori I. Br J Pharmacol 158 879-887 (2009)
  138. Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. Nguyen HN, Yang JM, Afkari Y, Park BH, Sesaki H, Devreotes PN, Iijima M. Proc Natl Acad Sci U S A 111 E2684-93 (2014)
  139. Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. Yang JM, Schiapparelli P, Nguyen HN, Igarashi A, Zhang Q, Abbadi S, Amzel LM, Sesaki H, Quiñones-Hinojosa A, Iijima M. Oncogene 36 3673-3685 (2017)
  140. Acute ethanol exposure inhibits insulin signaling in the liver. He J, de la Monte S, Wands JR. Hepatology 46 1791-1800 (2007)
  141. Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal injuries. Zhang S, Taghibiglou C, Girling K, Dong Z, Lin SZ, Lee W, Shyu WC, Wang YT. J Neurosci 33 7997-8008 (2013)
  142. MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Hu Y, Li Z, Guo L, Wang L, Zhang L, Cai X, Zhao H, Zha X. Arch Biochem Biophys 467 1-9 (2007)
  143. Neddylation of PTEN regulates its nuclear import and promotes tumor development. Xie P, Peng Z, Chen Y, Li H, Du M, Tan Y, Zhang X, Lu Z, Cui CP, Liu CH, He F, Zhang L. Cell Res 31 291-311 (2021)
  144. Phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a molecular target in lung epithelial wound repair. Lai JP, Dalton JT, Knoell DL. Br J Pharmacol 152 1172-1184 (2007)
  145. Ptena and ptenb genes play distinct roles in zebrafish embryogenesis. Croushore JA, Blasiole B, Riddle RC, Thisse C, Thisse B, Canfield VA, Robertson GP, Cheng KC, Levenson R. Dev Dyn 234 911-921 (2005)
  146. Trimeric structure of PRL-1 phosphatase reveals an active enzyme conformation and regulation mechanisms. Jeong DG, Kim SJ, Kim JH, Son JH, Park MR, Lim SM, Yoon TS, Ryu SE. J Mol Biol 345 401-413 (2005)
  147. Structure of human PRL-3, the phosphatase associated with cancer metastasis. Kim KA, Song JS, Jee J, Sheen MR, Lee C, Lee TG, Ro S, Cho JM, Lee W, Yamazaki T, Jeon YH, Cheong C. FEBS Lett 565 181-187 (2004)
  148. Research Support, Non-U.S. Gov't Nuclear PTEN: a tale of many tails. Gil A, Andrés-Pons A, Pulido R. Cell Death Differ 14 395-399 (2007)
  149. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. Li Y, Hu Q, Li C, Liang K, Xiang Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Ambati CR, Putluri N, Hawke DH, Han L, Hung MC, Danesh FR, Yang L, Lin C. J Clin Invest 129 1129-1151 (2019)
  150. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Song H, Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Fukushima Y, Kikuchi M, Shimano H, Yamada N, Oka Y, Asano T. Biochem Biophys Res Commun 299 291-298 (2002)
  151. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP. Biochem J 357 427-435 (2001)
  152. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G, Nand S, Breuer EK, Kuo PC, Breslin P, Kini AR, Nishimura MI, Zeleznik-Le NJ, Zhang J. Cell Rep 10 2055-2068 (2015)
  153. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, Breen M, Helfand SC, Modiano JF. Vet Pathol 42 618-632 (2005)
  154. PTEN inhibitors: an evaluation of current compounds. Spinelli L, Lindsay YE, Leslie NR. Adv Biol Regul 57 102-111 (2015)
  155. α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. He L, Fan C, Kapoor A, Ingram AJ, Rybak AP, Austin RC, Dickhout J, Cutz JC, Scholey J, Tang D. Nat Commun 2 307 (2011)
  156. Distinct functional outputs of PTEN signalling are controlled by dynamic association with β-arrestins. Lima-Fernandes E, Enslen H, Camand E, Kotelevets L, Boularan C, Achour L, Benmerah A, Gibson LC, Baillie GS, Pitcher JA, Chastre E, Etienne-Manneville S, Marullo S, Scott MG. EMBO J 30 2557-2568 (2011)
  157. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Meng Z, Jia LF, Gan YH. Oncogene 35 2333-2344 (2016)
  158. Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Hodakoski C, Hopkins BD, Barrows D, Mense SM, Keniry M, Anderson KE, Kern PA, Hawkins PT, Stephens LR, Parsons R. Proc Natl Acad Sci U S A 111 155-160 (2014)
  159. Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias. Schick V, Majores M, Engels G, Spitoni S, Koch A, Elger CE, Simon M, Knobbe C, Blümcke I, Becker AJ. Acta Neuropathol 112 715-725 (2006)
  160. Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity. Riquelme SA, Hopkins BD, Wolfe AL, DiMango E, Kitur K, Parsons R, Prince A. Immunity 47 1169-1181.e7 (2017)
  161. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Kanamori Y, Kigawa J, Itamochi H, Sultana H, Suzuki M, Ohwada M, Kamura T, Sugiyama T, Kikuchi Y, Kita T, Fujiwara K, Terakawa N. Int J Cancer 100 686-689 (2002)
  162. The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy. Malaney P, Uversky VN, Davé V. Mol Biosyst 9 2877-2888 (2013)
  163. A unified nomenclature and amino acid numbering for human PTEN. Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR. Sci Signal 7 pe15 (2014)
  164. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibition by 4-hydroxynonenal leads to increased Akt activation in hepatocytes. Shearn CT, Smathers RL, Stewart BJ, Fritz KS, Galligan JJ, Hail N, Petersen DR. Mol Pharmacol 79 941-952 (2011)
  165. Phosphotyrosine recognition domains: the typical, the atypical and the versatile. Kaneko T, Joshi R, Feller SM, Li SS. Cell Commun Signal 10 32 (2012)
  166. ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Chetram MA, Don-Salu-Hewage AS, Hinton CV. Biochem Biophys Res Commun 410 195-200 (2011)
  167. Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML. Rijal S, Fleming S, Cummings N, Rynkiewicz NK, Ooms LM, Nguyen NY, Teh TC, Avery S, McManus JF, Papenfuss AT, McLean C, Guthridge MA, Mitchell CA, Wei AH. Blood 125 2815-2824 (2015)
  168. Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium. Nguyen HN, Afkari Y, Senoo H, Sesaki H, Devreotes PN, Iijima M. Oncogene 33 5688-5696 (2014)
  169. PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow. Haier J, Nicolson GL. Oncogene 21 1450-1460 (2002)
  170. PTEN-inhibition by zinc ions augments interleukin-2-mediated Akt phosphorylation. Plum LM, Brieger A, Engelhardt G, Hebel S, Nessel A, Arlt M, Kaltenberg J, Schwaneberg U, Huber M, Rink L, Haase H. Metallomics 6 1277-1287 (2014)
  171. The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Penas C, Ramachandran V, Ayad NG. Front Oncol 1 60 (2011)
  172. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH. Neoplasia 20 574-593 (2018)
  173. Controlling the activity of a phosphatase and tensin homolog (PTEN) by membrane potential. Lacroix J, Halaszovich CR, Schreiber DN, Leitner MG, Bezanilla F, Oliver D, Villalba-Galea CA. J Biol Chem 286 17945-17953 (2011)
  174. PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage. Zhang J, Lee YR, Dang F, Gan W, Menon AV, Katon JM, Hsu CH, Asara JM, Tibarewal P, Leslie NR, Shi Y, Pandolfi PP, Wei W. Cancer Discov 9 1306-1323 (2019)
  175. Structural basis for the glucan phosphatase activity of Starch Excess4. Vander Kooi CW, Taylor AO, Pace RM, Meekins DA, Guo HF, Kim Y, Gentry MS. Proc Natl Acad Sci U S A 107 15379-15384 (2010)
  176. Structure of the PTEN-like region of auxilin, a detector of clathrin-coated vesicle budding. Guan R, Dai H, Harrison SC, Kirchhausen T. Structure 18 1191-1198 (2010)
  177. Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Torres J, Navarro S, Roglá I, Ripoll F, Lluch A, García-Conde J, Llombart-Bosch A, Cervera J, Pulido R. Eur J Cancer 37 114-121 (2001)
  178. Is there a biological cost of protein disorder? Analysis of cancer-associated mutations. Pajkos M, Mészáros B, Simon I, Dosztányi Z. Mol Biosyst 8 296-307 (2012)
  179. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Park MK, Yao Y, Xia W, Setijono SR, Kim JH, Vila IK, Chiu HH, Wu Y, Billalabeitia EG, Lee MG, Kalb RG, Hung MC, Pandolfi PP, Song SJ, Song MS. Nat Commun 10 636 (2019)
  180. Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J, Bartek J. Exp Cell Res 256 571-577 (2000)
  181. Correlation between synaptogenesis and the PTEN phosphatase expression in dendrites during postnatal brain development. Perandones C, Costanzo RV, Kowaljow V, Pivetta OH, Carminatti H, Radrizzani M. Brain Res Mol Brain Res 128 8-19 (2004)
  182. The neurosecretory vesicle protein phogrin functions as a phosphatidylinositol phosphatase to regulate insulin secretion. Caromile LA, Oganesian A, Coats SA, Seifert RA, Bowen-Pope DF. J Biol Chem 285 10487-10496 (2010)
  183. Hypoxia induces cardiac fibroblast proliferation and phenotypic switch: a role for caveolae and caveolin-1/PTEN mediated pathway. Gao Y, Chu M, Hong J, Shang J, Xu D. J Thorac Dis 6 1458-1468 (2014)
  184. Insight into the redox regulation of the phosphoglucan phosphatase SEX4 involved in starch degradation. Silver DM, Silva LP, Issakidis-Bourguet E, Glaring MA, Schriemer DC, Moorhead GB. FEBS J 280 538-548 (2013)
  185. Involvement of phosphoinositide 3-kinase and PTEN protein in mechanism of activation of TRPC6 protein in vascular smooth muscle cells. Monet M, Francoeur N, Boulay G. J Biol Chem 287 17672-17681 (2012)
  186. Mutual inhibition between PTEN and PIP3 generates bistability for polarity in motile cells. Matsuoka S, Ueda M. Nat Commun 9 4481 (2018)
  187. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. De Vivo I, Gertig DM, Nagase S, Hankinson SE, O'Brien R, Speizer FE, Parsons R, Hunter DJ. J Med Genet 37 336-341 (2000)
  188. PTEN stabilizes TOP2A and regulates the DNA decatenation. Kang X, Song C, Du X, Zhang C, Liu Y, Liang L, He J, Lamb K, Shen WH, Yin Y. Sci Rep 5 17873 (2015)
  189. Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6-pentakisphosphate 3-phosphatase activity. Caffrey JJ, Darden T, Wenk MR, Shears SB. FEBS Lett 499 6-10 (2001)
  190. Global profiling of distinct cysteine redox forms reveals wide-ranging redox regulation in C. elegans. Meng J, Fu L, Liu K, Tian C, Wu Z, Jung Y, Ferreira RB, Carroll KS, Blackwell TK, Yang J. Nat Commun 12 1415 (2021)
  191. LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. Hu Q, Li C, Wang S, Li Y, Wen B, Zhang Y, Liang K, Yao J, Ye Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Hawke DH, Marks JR, Han L, Hung MC, Zhang B, Lin C, Yang L. Cell Res 29 286-304 (2019)
  192. A critical step for postsynaptic F-actin organization: regulation of Baz/Par-3 localization by aPKC and PTEN. Ramachandran P, Barria R, Ashley J, Budnik V. Dev Neurobiol 69 583-602 (2009)
  193. Crystal structure of the catalytic domain of human MAP kinase phosphatase 5: structural insight into constitutively active phosphatase. Jeong DG, Yoon TS, Kim JH, Shim MY, Jung SK, Son JH, Ryu SE, Kim SJ. J Mol Biol 360 946-955 (2006)
  194. Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli. Bastola DR, Pahwa GS, Lin MF, Cheng PW. Mol Cell Biochem 236 75-81 (2002)
  195. Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2. Ding Z, Jian S, Peng X, Liu Y, Wang J, Zheng L, Ou C, Wang Y, Zeng W, Zhou M. Medicine (Baltimore) 94 e1327 (2015)
  196. PTEN mutation spectrum in breast cancers and breast hyperplasia. Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T, Dai F. J Cancer Res Clin Oncol 136 1303-1311 (2010)
  197. A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration. Cao X, Kaneko T, Li JS, Liu AD, Voss C, Li SS. Nat Commun 6 7721 (2015)
  198. Discovery and functional characterization of a neomorphic PTEN mutation. Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR, Bustamante CD. Proc Natl Acad Sci U S A 112 13976-13981 (2015)
  199. Enzymatic Analysis of PTEN Ubiquitylation by WWP2 and NEDD4-1 E3 Ligases. Chen Z, Thomas SN, Bolduc DM, Jiang X, Zhang X, Wolberger C, Cole PA. Biochemistry 55 3658-3666 (2016)
  200. The PTEN Tumor Suppressor Forms Homodimers in Solution. Heinrich F, Chakravarthy S, Nanda H, Papa A, Pandolfi PP, Ross AH, Harishchandra RK, Gericke A, Lösche M. Structure 23 1952-1957 (2015)
  201. A mutant form of PTEN linked to autism. Redfern RE, Daou MC, Li L, Munson M, Gericke A, Ross AH. Protein Sci 19 1948-1956 (2010)
  202. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Konopka B, Paszko Z, Janiec-Jankowska A, Goluda M. Cancer Lett 178 43-51 (2002)
  203. Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock. Li Y, Alam HB. Adv Exp Med Biol 710 107-133 (2012)
  204. Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function. He D, Xu H, Zhang H, Tang R, Lan Y, Xing R, Li S, Christian E, Hou Y, Lorello P, Caldarone B, Ding J, Nguyen L, Dionne D, Thakore P, Schnell A, Huh JR, Rozenblatt-Rosen O, Regev A, Kuchroo VK. Immunity 55 159-173.e9 (2022)
  205. Honey bee PTEN--description, developmental knockdown, and tissue-specific expression of splice-variants correlated with alternative social phenotypes. Mutti NS, Wang Y, Kaftanoglu O, Amdam GV. PLoS One 6 e22195 (2011)
  206. Magnolol-induced H460 cells death via autophagy but not apoptosis. Li HB, Yi X, Gao JM, Ying XX, Guan HQ, Li JC. Arch Pharm Res 30 1566-1574 (2007)
  207. Structural insights into glucan phosphatase dynamics using amide hydrogen-deuterium exchange mass spectrometry. Hsu S, Kim Y, Li S, Durrant ES, Pace RM, Woods VL, Gentry MS. Biochemistry 48 9891-9902 (2009)
  208. A new class of cancer-associated PTEN mutations defined by membrane translocation defects. Nguyen HN, Yang JM, Rahdar M, Keniry M, Swaney KF, Parsons R, Park BH, Sesaki H, Devreotes PN, Iijima M. Oncogene 34 3737-3743 (2015)
  209. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA. Cancer Res 76 4850-4860 (2016)
  210. Multi-model functionalization of disease-associated PTEN missense mutations identifies multiple molecular mechanisms underlying protein dysfunction. Post KL, Belmadani M, Ganguly P, Meili F, Dingwall R, McDiarmid TA, Meyers WM, Herrington C, Young BP, Callaghan DB, Rogic S, Edwards M, Niciforovic A, Cau A, Rankin CH, O'Connor TP, Bamji SX, Loewen CJR, Allan DW, Pavlidis P, Haas K. Nat Commun 11 2073 (2020)
  211. Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Zhang L, Yu Q, He J, Zha X. Mol Cell Biochem 262 25-33 (2004)
  212. The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ. Alonso A, Burkhalter S, Sasin J, Tautz L, Bogetz J, Huynh H, Bremer MC, Holsinger LJ, Godzik A, Mustelin T. J Biol Chem 279 35768-35774 (2004)
  213. Modulation of microRNAs in hypertension-induced arterial remodeling through the β1 and β3-adrenoreceptor pathways. Ling S, Nanhwan M, Qian J, Kodakandla M, Castillo AC, Thomas B, Liu H, Ye Y. J Mol Cell Cardiol 65 127-136 (2013)
  214. Phosphorylation of the actin binding protein Drebrin at S647 is regulated by neuronal activity and PTEN. Kreis P, Hendricusdottir R, Kay L, Papageorgiou IE, van Diepen M, Mack T, Ryves J, Harwood A, Leslie NR, Kann O, Parsons M, Eickholt BJ. PLoS One 8 e71957 (2013)
  215. Therapeutic Implications of Targeting AKT Signaling in Melanoma. Madhunapantula SV, Robertson GP. Enzyme Res 2011 327923 (2011)
  216. A PTEN-related 5-phosphatidylinositol phosphatase localized in the Golgi. Merlot S, Meili R, Pagliarini DJ, Maehama T, Dixon JE, Firtel RA. J Biol Chem 278 39866-39873 (2003)
  217. A novel class of PTEN protein in Arabidopsis displays unusual phosphoinositide phosphatase activity and efficiently binds phosphatidic acid. Pribat A, Sormani R, Rousseau-Gueutin M, Julkowska MM, Testerink C, Joubès J, Castroviejo M, Laguerre M, Meyer C, Germain V, Rothan C. Biochem J 441 161-171 (2012)
  218. Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. Liu J, Lu H, Ohgaki H, Merlo A, Shen Z. BMC Cancer 9 268 (2009)
  219. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Yeung YT, Fan S, Lu B, Yin S, Yang S, Nie W, Wang M, Zhou L, Li T, Li X, Bode AM, Dong Z. Carcinogenesis 41 377-389 (2020)
  220. Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines. Ma DZ, Xu Z, Liang YL, Su JM, Li ZX, Zhang W, Wang LY, Zha XL. World J Gastroenterol 11 4472-4477 (2005)
  221. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. Narayan S, Bader GD, Reimand J. Genome Med 8 55 (2016)
  222. Location of auxilin within a clathrin cage. Smith CJ, Dafforn TR, Kent H, Sims CA, Khubchandani-Aswani K, Zhang L, Saibil HR, Pearse BM. J Mol Biol 336 461-471 (2004)
  223. Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. He X, Ni Y, Wang Y, Romigh T, Eng C. Hum Mol Genet 20 80-89 (2011)
  224. A naphthoquinone derivative, shikonin, has insulin-like actions by inhibiting both phosphatase and tensin homolog deleted on chromosome 10 and tyrosine phosphatases. Nigorikawa K, Yoshikawa K, Sasaki T, Iida E, Tsukamoto M, Murakami H, Maehama T, Hazeki K, Hazeki O. Mol Pharmacol 70 1143-1149 (2006)
  225. Effects of PTEN on the proliferation and apoptosis of colorectal cancer cells via the phosphoinositol-3-kinase/Akt pathway. Sun Y, Tian H, Wang L. Oncol Rep 33 1828-1836 (2015)
  226. Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, Srivastava A, Yu L, Wallace J, Mo X, Park M, Fernandez SA, Pilarski R, La Perle KM, Rosol TJ, Coppola V, Castrillon DH, Timmers C, Cohn DE, O'Malley DM, Backes F, Suarez AA, Goodfellow P, Chamberlin HM, Macrae ER, Shapiro CL, Ostrowski MC, Leone G. Genes Dev 29 1707-1720 (2015)
  227. PTEN: a promising pharmacological target to enhance epithelial wound healing. Zhao M. Br J Pharmacol 152 1141-1144 (2007)
  228. Voltage-dependent motion of the catalytic region of voltage-sensing phosphatase monitored by a fluorescent amino acid. Sakata S, Jinno Y, Kawanabe A, Okamura Y. Proc Natl Acad Sci U S A 113 7521-7526 (2016)
  229. Analysis of phosphatase and tensin homolog tumor suppressor interacting proteins by in vitro and in silico proteomics. Crockett DK, Fillmore GC, Elenitoba-Johnson KS, Lim MS. Proteomics 5 1250-1262 (2005)
  230. Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia. Schwarzer A, Holtmann H, Brugman M, Meyer J, Schauerte C, Zuber J, Steinemann D, Schlegelberger B, Li Z, Baum C. Oncogene 34 3593-3604 (2015)
  231. Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome. Wan X, Dennis AT, Obejero-Paz C, Overholt JL, Heredia-Moya J, Kirk KL, Ficker E. J Biol Chem 286 2843-2852 (2011)
  232. PTEN/PI3K and MAPK signaling in protection and pathology following CNS injuries. Walker CL, Liu NK, Xu XM. Front Biol (Beijing) 8 (2013)
  233. Phloretin induces cell cycle arrest and apoptosis of human glioblastoma cells through the generation of reactive oxygen species. Liu Y, Fan C, Pu L, Wei C, Jin H, Teng Y, Zhao M, Yu AC, Jiang F, Shu J, Li F, Peng Q, Kong J, Pan B, Zheng L, Huang Y. J Neurooncol 128 217-223 (2016)
  234. Structural basis for interdomain communication in SHIP2 providing high phosphatase activity. Le Coq J, Camacho-Artacho M, Velázquez JV, Santiveri CM, Gallego LH, Campos-Olivas R, Dölker N, Lietha D. Elife 6 e26640 (2017)
  235. The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. He J, de la Monte S, Wands JR. Biochem Biophys Res Commun 397 513-519 (2010)
  236. Application of phosphoinositide-binding domains for the detection and quantification of specific phosphoinositides. Furutani M, Tsujita K, Itoh T, Ijuin T, Takenawa T. Anal Biochem 355 8-18 (2006)
  237. Catalysis by the tumor-suppressor enzymes PTEN and PTEN-L. Johnston SB, Raines RT. PLoS One 10 e0116898 (2015)
  238. Crystal structure of the catalytic domain of human DUSP5, a dual specificity MAP kinase protein phosphatase. Jeong DG, Cho YH, Yoon TS, Kim JH, Ryu SE, Kim SJ. Proteins 66 253-258 (2007)
  239. PTEN loss correlates with T cell exclusion across human cancers. Lin Z, Huang L, Li SL, Gu J, Cui X, Zhou Y. BMC Cancer 21 429 (2021)
  240. PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Ge H, Cao YY, Chen LQ, Wang YM, Chen ZF, Wen DG, Zhang XF, Guo W, Wang N, Li Y, Zhang JH. Dis Esophagus 21 409-415 (2008)
  241. Ptenb mediates gastrulation cell movements via Cdc42/AKT1 in zebrafish. Yeh CM, Liu YC, Chang CJ, Lai SL, Hsiao CD, Lee SJ. PLoS One 6 e18702 (2011)
  242. A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity. Gil A, Rodríguez-Escudero I, Stumpf M, Molina M, Cid VJ, Pulido R. PLoS One 10 e0119287 (2015)
  243. A novel germline mutation of PTEN associated with brain tumours of multiple lineages. Staal FJ, van der Luijt RB, Baert MR, van Drunen J, van Bakel H, Peters E, de Valk I, van Amstel HK, Taphoorn MJ, Jansen GH, van Veelen CW, Burgering B, Staal GE. Br J Cancer 86 1586-1591 (2002)
  244. Coupling of Ci-VSP modules requires a combination of structure and electrostatics within the linker. Hobiger K, Utesch T, Mroginski MA, Friedrich T. Biophys J 102 1313-1322 (2012)
  245. Crystal structure of the MAP kinase binding domain and the catalytic domain of human MKP5. Tao X, Tong L. Protein Sci 16 880-886 (2007)
  246. Graph-Theoretic Analysis of Monomethyl Phosphate Clustering in Ionic Solutions. Han K, Venable RM, Bryant AM, Legacy CJ, Shen R, Li H, Roux B, Gericke A, Pastor RW. J Phys Chem B 122 1484-1494 (2018)
  247. Induction of Akt phosphorylation in rat primary astrocytes by H2O2 occurs upstream of phosphatidylinositol 3-kinase: no evidence for oxidative inhibition of PTEN. Salsman S, Felts N, Pye QN, Floyd RA, Hensley K. Arch Biochem Biophys 386 275-280 (2001)
  248. PTEN hopping on the cell membrane is regulated via a positively-charged C2 domain. Yasui M, Matsuoka S, Ueda M. PLoS Comput Biol 10 e1003817 (2014)
  249. PTEN is required for the normal progression of gastrulation by repressing cell proliferation after MBT in Xenopus embryos. Ueno S, Kono R, Iwao Y. Dev Biol 297 274-283 (2006)
  250. Phosphatidylinositol 3,4,5-trisphosphate: an early mediator of insulin-stimulated sodium transport in A6 cells. Markadieu N, Blero D, Boom A, Erneux C, Beauwens R. Am J Physiol Renal Physiol 287 F319-28 (2004)
  251. Voltage-Controlled Enzymes: The New JanusBifrons. Villalba-Galea CA. Front Pharmacol 3 161 (2012)
  252. Inhibition of phosphatase and tensin homolog deleted on chromosome 10 decreases rat cortical neuron injury and blood-brain barrier permeability, and improves neurological functional recovery in traumatic brain injury model. Ding J, Guo J, Yuan Q, Yuan F, Chen H, Tian H. PLoS One 8 e80429 (2013)
  253. Nuclear Excluded Autism-Associated Phosphatase and Tensin Homolog Mutations Dysregulate Neuronal Growth. Fricano-Kugler CJ, Getz SA, Williams MR, Zurawel AA, DeSpenza T, Frazel PW, Li M, O'Malley AJ, Moen EL, Luikart BW. Biol Psychiatry 84 265-277 (2018)
  254. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Zu L, Shen Z, Wesley J, Cai ZP. Eur J Pharmacol 650 298-302 (2011)
  255. Pharmacological Inhibition of PTEN Aggravates Acute Kidney Injury. Zhou J, Jia L, Hu Z, Wang Y. Sci Rep 7 9503 (2017)
  256. Polysulfide Na2S4 regulates the activation of PTEN/Akt/CREB signaling and cytotoxicity mediated by 1,4-naphthoquinone through formation of sulfur adducts. Abiko Y, Shinkai Y, Unoki T, Hirose R, Uehara T, Kumagai Y. Sci Rep 7 4814 (2017)
  257. The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. Giudice FS, Squarize CH. J Carcinog Mutagen Suppl 5 003 (2013)
  258. Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity. He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cancer Res 73 3029-3040 (2013)
  259. Enzyme-substrate interactions revealed by the crystal structures of the archaeal Sulfolobus PTP-fold phosphatase and its phosphopeptide complexes. Chu HM, Wang AH. Proteins 66 996-1003 (2007)
  260. Interactions of the auxilin-1 PTEN-like domain with model membranes result in nanoclustering of phosphatidyl inositol phosphates. Kalli AC, Morgan G, Sansom MS. Biophys J 105 137-145 (2013)
  261. Opening the conformation is a master switch for the dual localization and phosphatase activity of PTEN. Nguyen HN, Yang JM, Miyamoto T, Itoh K, Rho E, Zhang Q, Inoue T, Devreotes PN, Sesaki H, Iijima M. Sci Rep 5 12600 (2015)
  262. A new family of phosphoinositide phosphatases in microorganisms: identification and biochemical analysis. Beresford NJ, Saville C, Bennett HJ, Roberts IS, Tabernero L. BMC Genomics 11 457 (2010)
  263. A new insight into structural and functional impact of single-nucleotide polymorphisms in PTEN gene. George Priya Doss C, Rajith B. Cell Biochem Biophys 66 249-263 (2013)
  264. Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro. Dery MC, Van Themsche C, Provencher D, Mes-Masson AM, Asselin E. Reprod Biol Endocrinol 5 38 (2007)
  265. Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line. Singh G, Odriozola L, Guan H, Kennedy CR, Chan AM. BMC Cancer 11 490 (2011)
  266. Expression of the PTEN tumor suppressor gene in malignant mammary gland tumors of dogs. Kanae Y, Endoh D, Yokota H, Taniyama H, Hayashi M. Am J Vet Res 67 127-133 (2006)
  267. Individual domains of Tensin2 exhibit distinct subcellular localisations and migratory effects. Hafizi S, Sernstad E, Swinny JD, Gomez MF, Dahlbäck B. Int J Biochem Cell Biol 42 52-61 (2010)
  268. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Singh AR, Peirce SK, Joshi S, Durden DL. Exp Cell Res 327 78-90 (2014)
  269. PTEN phosphatase-independent maintenance of glandular morphology in a predictive colorectal cancer model system. Jagan IC, Deevi RK, Fatehullah A, Topley R, Eves J, Stevenson M, Loughrey M, Arthur K, Campbell FC. Neoplasia 15 1218-1230 (2013)
  270. PTEN-Foxo1 signaling triggers HMGB1-mediated innate immune responses in acute lung injury. Zhou M, Zhang Y, Chen X, Zhu J, Du M, Zhou L, Zhang L, Wang W, Sun G. Immunol Res 62 95-105 (2015)
  271. Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. Qian J, Ling S, Castillo AC, Long B, Birnbaum Y, Ye Y. Am J Physiol Heart Circ Physiol 302 H1806-17 (2012)
  272. A pathogenic role for germline PTEN variants which accumulate into the nucleus. Mingo J, Rodríguez-Escudero I, Luna S, Fernández-Acero T, Amo L, Jonasson AR, Zori RT, López JI, Molina M, Cid VJ, Pulido R. Eur J Hum Genet 26 1180-1187 (2018)
  273. Casein kinase 2 dependent phosphorylation of neprilysin regulates receptor tyrosine kinase signaling to Akt. Siepmann M, Kumar S, Mayer G, Walter J. PLoS One 5 e13134 (2010)
  274. Crystal structure of the catalytic domain of human MKP-2 reveals a 24-mer assembly. Jeong DG, Jung SK, Yoon TS, Woo EJ, Kim JH, Park BC, Ryu SE, Kim SJ. Proteins 76 763-767 (2009)
  275. Distinguishing between PTEN clinical phenotypes through mutation analysis. Portelli S, Barr L, de Sá AGC, Pires DEV, Ascher DB. Comput Struct Biotechnol J 19 3097-3109 (2021)
  276. Inhibition of U6 snRNA Transcription by PTEN. Cabarcas S, Watabe K, Schramm L. Online J Biol Sci 10 114-125 (2010)
  277. Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. Yang YC, Ho TC, Chen SL, Lai HY, Wu JY, Tsao YP. BMC Cancer 7 216 (2007)
  278. Insights into the catalytic mechanism of human sEH phosphatase by site-directed mutagenesis and LC-MS/MS analysis. Cronin A, Homburg S, Dürk H, Richter I, Adamska M, Frère F, Arand M. J Mol Biol 383 627-640 (2008)
  279. Structural characterization of the C2 domain of novel protein kinase Cepsilon. García-García J, Gómez-Fernández JC, Corbalán-García S. Eur J Biochem 268 1107-1117 (2001)
  280. A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease. Vega A, Torres J, Torres M, Cameselle-Teijeiro J, Macia M, Carracedo A, Pulido R. J Invest Dermatol 121 1356-1359 (2003)
  281. Analysis of Site-Specific Phosphorylation of PTEN by Using Enzyme-Catalyzed Expressed Protein Ligation. Henager SH, Henriquez S, Dempsey DR, Cole PA. Chembiochem 21 64-68 (2020)
  282. Conserved synteny between the Fugu and human PTEN locus and the evolutionary conservation of vertebrate PTEN function. Yu WP, Pallen CJ, Tay A, Jirik FR, Brenner S, Tan YH, Venkatesh B. Oncogene 20 5554-5561 (2001)
  283. Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities. Lopez SM, Hodgson MC, Packianathan C, Bingol-Ozakpinar O, Uras F, Rosen BP, Agoulnik IU. Biochem Biophys Res Commun 440 277-282 (2013)
  284. Functional definition of relevant epitopes on the tumor suppressor PTEN protein. Andrés-Pons A, Valiente M, Torres J, Gil A, Roglá I, Ripoll F, Cervera J, Pulido R. Cancer Lett 223 303-312 (2005)
  285. Identification of a PTEN mutation with reduced protein stability, phosphatase activity, and nuclear localization in Hong Kong patients with autistic features, neurodevelopmental delays, and macrocephaly. Wong CW, Or PMY, Wang Y, Li L, Li J, Yan M, Cao Y, Luk HM, Tong TMF, Leslie NR, Lo IF, Choy KW, Chan AML. Autism Res 11 1098-1109 (2018)
  286. Phosphatase and tensin homologue deleted on chromosome 10. Abdulkareem IH, Blair M. Niger Med J 54 79-86 (2013)
  287. Phylogenetic and genetic linkage between novel atypical dual-specificity phosphatases from non-metazoan organisms. Romá-Mateo C, Sacristán-Reviriego A, Beresford NJ, Caparrós-Martín JA, Culiáñez-Macià FA, Martín H, Molina M, Tabernero L, Pulido R. Mol Genet Genomics 285 341-354 (2011)
  288. Protein transduction: generation of full-length transducible proteins using the TAT system. Becker-Hapak M, Dowdy SF. Curr Protoc Cell Biol Chapter 20 Unit 20.2 (2003)
  289. Reciprocal Relationship between Head Size, an Autism Endophenotype, and Gene Dosage at 19p13.12 Points to AKAP8 and AKAP8L. Nebel RA, Kirschen J, Cai J, Woo YJ, Cherian K, Abrahams BS. PLoS One 10 e0129270 (2015)
  290. Salvianolic acid A positively regulates PTEN protein level and inhibits growth of A549 lung cancer cells. Bi L, Chen J, Yuan X, Jiang Z, Chen W. Biomed Rep 1 213-217 (2013)
  291. The tumor suppressor PTEN regulates motor responses to striatal dopamine in normal and Parkinsonian animals. Stavarache MA, Musatov S, McGill M, Vernov M, Kaplitt MG. Neurobiol Dis 82 487-494 (2015)
  292. A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells. Lima-Fernandes E, Misticone S, Boularan C, Paradis JS, Enslen H, Roux PP, Bouvier M, Baillie GS, Marullo S, Scott MG. Nat Commun 5 4431 (2014)
  293. Asymmetric PTEN distribution regulated by spatial heterogeneity in membrane-binding state transitions. Matsuoka S, Shibata T, Ueda M. PLoS Comput Biol 9 e1002862 (2013)
  294. BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation. Li AG, Murphy EC, Culhane AC, Powell E, Wang H, Bronson RT, Von T, Giobbie-Hurder A, Gelman RS, Briggs KJ, Piwnica-Worms H, Zhao JJ, Kung AL, Kaelin WG, Livingston DM. Proc Natl Acad Sci U S A 115 E9600-E9609 (2018)
  295. Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN. Martin SA, Ouchi T. Mol Cancer Ther 7 2509-2516 (2008)
  296. Crystal structure of the major diabetes autoantigen insulinoma-associated protein 2 reveals distinctive immune epitopes. Kim SJ, Jeong DG, Jeong SK, Yoon TS, Ryu SE. Diabetes 56 41-48 (2007)
  297. Integrating virtual and biochemical screening for protein tyrosine phosphatase inhibitor discovery. Martin KR, Narang P, Medina-Franco JL, Meurice N, MacKeigan JP. Methods 65 219-228 (2014)
  298. PTEN controls glandular morphogenesis through a juxtamembrane β-Arrestin1/ARHGAP21 scaffolding complex. Javadi A, Deevi RK, Evergren E, Blondel-Tepaz E, Baillie GS, Scott MG, Campbell FC. Elife 6 e24578 (2017)
  299. PTEN does not modulate GLUT4 translocation in rat adipose cells under physiological conditions. Mosser VA, Li Y, Quon MJ, Quon MJ. Biochem Biophys Res Commun 288 1011-1017 (2001)
  300. Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Sharrard RM, Maitland NJ. Br J Cancer 83 1102-1109 (2000)
  301. Podocyte-specific knockin of PTEN protects kidney from hyperglycemia. Wang H, Feng Z, Xie J, Wen F, Jv M, Liang T, Li J, Wang Y, Zuo Y, Li S, Li R, Li Z, Zhang B, Liang X, Liu S, Shi W, Wang W. Am J Physiol Renal Physiol 314 F1096-F1107 (2018)
  302. The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways. Muro I, Fang G, Gardella KA, Mahajan IM, Wright CW. Cell Cycle 13 1918-1927 (2014)
  303. 3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth. Hu Y, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. Bioorg Med Chem Lett 11 173-176 (2001)
  304. Characterization of Specific Ion Effects on PI(4,5)P2 Clustering: Molecular Dynamics Simulations and Graph-Theoretic Analysis. Han K, Gericke A, Pastor RW. J Phys Chem B 124 1183-1196 (2020)
  305. Differential Requirement for Pten Lipid and Protein Phosphatase Activity during Zebrafish Embryonic Development. Stumpf M, den Hertog J. PLoS One 11 e0148508 (2016)
  306. Published Erratum Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB. Cancer Cell 35 816 (2019)
  307. Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression. Poole W, Leinonen K, Shmulevich I, Knijnenburg TA, Bernard B. PLoS Comput Biol 13 e1005347 (2017)
  308. Editorial PTEN, here, there, everywhere. Bassi C, Stambolic V. Cell Death Differ 20 1595-1596 (2013)
  309. Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology. Mingo J, Luna S, Gaafar A, Nunes-Xavier CE, Torices L, Mosteiro L, Ruiz R, Guerra I, Llarena R, Angulo JC, López JI, Pulido R. NPJ Precis Oncol 3 11 (2019)
  310. RGS12 Represses Oral Cancer via the Phosphorylation and SUMOylation of PTEN. Fu C, Yuan G, Yang ST, Zhang D, Yang S. J Dent Res 100 522-531 (2021)
  311. Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells. Scully MM, Palacios-Helgeson LK, Wah LS, Jackson TA. Horm Cancer 5 218-231 (2014)
  312. Structural analysis of a multifunctional, tandemly repeated inositol polyphosphatase. Gruninger RJ, Selinger LB, Mosimann SC. J Mol Biol 392 75-86 (2009)
  313. TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. Akizuki K, Sekine M, Kogure Y, Kameda T, Shide K, Koya J, Kamiunten A, Kubuki Y, Tahira Y, Hidaka T, Kiwaki T, Tanaka H, Sato Y, Kataoka H, Kataoka K, Shimoda K. BMC Cancer 20 5 (2020)
  314. Characterization of phosphatase and tensin homolog expression in the mosquito Aedes aegypti: six splice variants with developmental and tissue specificity. Riehle MA, Brown JM. Insect Mol Biol 16 277-286 (2007)
  315. Crystal structure of human TMDP, a testis-specific dual specificity protein phosphatase: implications for substrate specificity. Kim SJ, Jeong DG, Yoon TS, Son JH, Cho SK, Ryu SE, Kim JH. Proteins 66 239-245 (2007)
  316. Crystal structure of human slingshot phosphatase 2. Jung SK, Jeong DG, Yoon TS, Kim JH, Ryu SE, Kim SJ. Proteins 68 408-412 (2007)
  317. Dimeric quaternary structure of human laforin. Sankhala RS, Koksal AC, Ho L, Nitschke F, Minassian BA, Cingolani G. J Biol Chem 290 4552-4559 (2015)
  318. Direct regulation of transforming growth factor β-induced epithelial-mesenchymal transition by the protein phosphatase activity of unphosphorylated PTEN in lung cancer cells. Kusunose M, Hashimoto N, Kimura M, Ogata R, Aoyama D, Sakamoto K, Miyazaki S, Ando A, Omote N, Imaizumi K, Kawabe T, Hasegawa Y. Cancer Sci 106 1693-1704 (2015)
  319. Molecular characterization and function of a PTEN gene from Litopenaeus vannamei after Vibrio alginolyticus challenge. Xie CY, Kong JR, Zhao CS, Xiao YC, Peng T, Liu Y, Wang WN. Dev Comp Immunol 59 77-88 (2016)
  320. Mutational analysis of the PTEN gene and its effects in esophageal squamous cell carcinoma. Hou G, Lu Z, Liu M, Liu H, Xue L. Dig Dis Sci 56 1315-1322 (2011)
  321. Plasmodium falciparum double C2 domain protein, PfDOC2, binds to calcium when associated with membranes. Jean S, Zapata-Jenks MA, Farley JM, Tracy E, Mayer DC. Exp Parasitol 144 91-95 (2014)
  322. Prediction of functionally significant single nucleotide polymorphisms in PTEN tumor suppressor gene: An in silico approach. Khan I, Ansari IA, Singh P, Dass J FP. Biotechnol Appl Biochem 64 657-666 (2017)
  323. Suppression of a phosphatidylinositol 3-kinase signal by a specific spliced variant of Drosophila PTEN. Maehama T, Kosaka N, Okahara F, Takeuchi K, Umeda M, Dixon JE, Kanaho Y. FEBS Lett 565 43-47 (2004)
  324. The Sac domain-containing phosphoinositide phosphatases: structure, function, and disease. Hsu F, Mao Y. Front Biol (Beijing) 8 395-407 (2013)
  325. The linker pivot in Ci-VSP: the key to unlock catalysis. Hobiger K, Utesch T, Mroginski MA, Seebohm G, Friedrich T. PLoS One 8 e70272 (2013)
  326. UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma. Gui L, Zhang S, Xu Y, Zhang H, Zhu Y, Kong L. Cell Death Discov 7 357 (2021)
  327. A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human and mouse tissues, strongly inhibits cell growth in HeLa cells. Mishra RR, Chaudhary JK, Bajaj GD, Rath PC. PLoS One 6 e28433 (2011)
  328. Crystal structure of the catalytic domain of human VHY, a dual-specificity protein phosphatase. Yoon TS, Jeong DG, Kim JH, Cho YH, Son JH, Lee JW, Ryu SE, Kim SJ. Proteins 61 694-697 (2005)
  329. Functional diversity of voltage-sensing phosphatases in two urodele amphibians. Mutua J, Jinno Y, Sakata S, Okochi Y, Ueno S, Tsutsui H, Kawai T, Iwao Y, Okamura Y. Physiol Rep 2 e12061 (2014)
  330. Striking a balance: PIP2 and PIP3 signaling in neuronal health and disease. Tariq K, Luikart BW. Explor Neuroprotective Ther 1 86-100 (2021)
  331. Autism-associated PTEN missense mutation leads to enhanced nuclear localization and neurite outgrowth in an induced pluripotent stem cell line. Wong CW, Wang Y, Liu T, Li L, Cheung SKK, Or PM, Cheng AS, Choy KW, Burbach JPH, Feng B, Chang RCC, Chan AM. FEBS J 287 4848-4861 (2020)
  332. Biochemical characterization of the type I inositol polyphosphate 4-phosphatase C2 domain. Shearn CT, Norris FA. Biochem Biophys Res Commun 356 255-259 (2007)
  333. Cell cycle arrest and apoptosis by expression of a novel TPIP (TPIP-C2) cDNA encoding a C2-domain in HEK-293 cells. Mishra RR, Chaudhary JK, Rath PC. Mol Biol Rep 39 7389-7402 (2012)
  334. Different conformations of phosphatase and tensin homolog, deleted on chromosome 10 (PTEN) protein within the nucleus and cytoplasm of neurons. Moncalero VL, Costanzo RV, Perandones C, Radrizzani M. PLoS One 6 e18857 (2011)
  335. PTEN Inhibits Inflammatory Bone Loss in Ligature-Induced Periodontitis via IL1 and TNF-α. Fu C, Wei Z, Zhang D. Biomed Res Int 2019 6712591 (2019)
  336. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. Cell Rep 28 2317-2330.e8 (2019)
  337. dTBC1D7 regulates systemic growth independently of TSC through insulin signaling. Ren S, Huang Z, Jiang Y, Wang T. J Cell Biol 217 517-526 (2018)
  338. Fine-Tuning of Pten Localization and Phosphatase Activity Is Essential for Zebrafish Angiogenesis. Stumpf M, Blokzijl-Franke S, den Hertog J. PLoS One 11 e0154771 (2016)
  339. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. Orbo A, Kaino T, Arnes M, Kopp M, Eklo K. Gynecol Oncol 95 82-88 (2004)
  340. Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Schöndorf T, Becker M, Göhring UJ, Wappenschmidt B, Kolhagen H, Kurbacher CM. Anticancer Drugs 12 797-800 (2001)
  341. Kinetics of PTEN-mediated PI(3,4,5)P3 hydrolysis on solid supported membranes. Liu C, Deb S, Ferreira VS, Xu E, Baumgart T. PLoS One 13 e0192667 (2018)
  342. Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain. Falke JJ. Cellscience 4 25-30 (2007)
  343. Rapid adaptive evolution of the tumor suppressor gene Pten in an insect lineage. Baudry E, Desmadril M, Werren JH. J Mol Evol 62 738-744 (2006)
  344. Structural and biochemical analysis of a unique phosphatase from Bdellovibrio bacteriovorus reveals its structural and functional relationship with the protein tyrosine phosphatase class of phytase. Gruninger RJ, Thibault J, Capeness MJ, Till R, Mosimann SC, Sockett RE, Selinger BL, Lovering AL. PLoS One 9 e94403 (2014)
  345. Synchronous bilateral breast carcinoma in a patient with cowden syndrome: a case report with morphologic, immunohistochemical and genetic analysis. Peiró G, Adrover E, Guijarro J, Ballester I, Jimenez MJ, Planelles M, Catasús L. Breast J 16 77-81 (2010)
  346. Comment A motor driving PTEN. Zhou J, Parada LF. Nat Cell Biol 11 1177-1179 (2009)
  347. Association between PTEN Gene IVS4 polymorphism and risk of cancer: a meta-analysis. Sun L, Liu J, Yuan Q, Xing C, Yuan Y. PLoS One 9 e98851 (2014)
  348. Doxycyclin ameliorates a starvation-induced germline tumor in C. elegans daf-18/PTEN mutant background. Wolf T, Qi W, Schindler V, Runkel ED, Baumeister R. Exp Gerontol 56 114-122 (2014)
  349. Expression of Human PTEN-L in a Yeast Heterologous Model Unveils Specific N-Terminal Motifs Controlling PTEN-L Subcellular Localization and Function. Fernández-Acero T, Bertalmio E, Luna S, Mingo J, Bravo-Plaza I, Rodríguez-Escudero I, Molina M, Pulido R, Cid VJ. Cells 8 E1512 (2019)
  350. Hypoxia potentiates the capacity of melanoma cells to evade cisplatin and doxorubicin cytotoxicity via glycolytic shift. Zhuo M, Gorgun FM, Tyler DS, Englander EW. FEBS Open Bio 10 789-801 (2020)
  351. Single-molecule imaging of PI(4,5)P2 and PTEN in vitro reveals a positive feedback mechanism for PTEN membrane binding. Yoshioka D, Fukushima S, Koteishi H, Okuno D, Ide T, Matsuoka S, Ueda M. Commun Biol 3 92 (2020)
  352. Structural basis for the dephosphorylating activity of PTPRQ towards phosphatidylinositide substrates. Yu KR, Kim YJ, Jung SK, Ku B, Park H, Cho SY, Jung H, Chung SJ, Bae KH, Lee SC, Kim BY, Erikson RL, Ryu SE, Kim SJ. Acta Crystallogr D Biol Crystallogr 69 1522-1529 (2013)
  353. Cross-Cancer Pleiotropic Analysis Reveals Novel Susceptibility Loci for Lung Cancer. Wang L, Zhu M, Wang Y, Fan J, Sun Q, Ji M, Fan X, Xie J, Dai J, Jin G, Hu Z, Ma H, Shen H. Front Oncol 9 1492 (2019)
  354. MN1 and PTEN gene expression in acute myeloid leukemia. Zayed RA, Eltaweel MA, Botros SK, Zaki MA. Cancer Biomark 18 177-182 (2017)
  355. Molecular Architecture of the Inositol Phosphatase Siw14. Florio TJ, Lokareddy RK, Gillilan RE, Cingolani G. Biochemistry 58 534-545 (2019)
  356. Alternative Splicing of MoPTEN Is Important for Growth and Pathogenesis in Magnaporthe oryzae. Wang S, Liang H, Wei Y, Zhang P, Dang Y, Li G, Zhang SH. Front Microbiol 12 715773 (2021)
  357. Assaying PTEN catalysis in vitro. Spinelli L, Leslie NR. Methods 77-78 51-57 (2015)
  358. Cell proliferation activity delineated by molecular docking of four new compounds isolated from the aerial parts of Suaeda monoica Forssk. ex. J.F. Gmel. Siddiqui NA, Mothana RA, Al-Said MS, Parvez MK, Alam P, Tabish Rehman M, Ali M, Alajmi MF, Al-Dosari MS, Al-Rehaily AJ, Nasr FA, Khalid JM. Saudi Pharm J 28 172-186 (2020)
  359. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma. Liao W, Du J, Li L, Wu X, Chen X, Feng Q, Xu L, Chen X, Liao M, Huang J, Yuan K, Zeng Y. J Exp Clin Cancer Res 42 125 (2023)
  360. Effects of PTEN on the longevity of cultured human umbilical vein endothelial cells: the role of antioxidants. Tait IS, Li Y, Lu J. Int J Mol Med 35 277-284 (2015)
  361. Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease. Torices L, Mingo J, Rodríguez-Escudero I, Fernández-Acero T, Luna S, Nunes-Xavier CE, López JI, Mercadillo F, Currás M, Urioste M, Molina M, Cid VJ, Pulido R. Eur J Hum Genet 31 568-577 (2023)
  362. Genetic analysis of daf-18/PTEN missense mutants for starvation resistance and developmental regulation during Caenorhabditis elegans L1 arrest. Chen J, Tang LY, Powell ME, Jordan JM, Baugh LR. G3 (Bethesda) 12 jkac092 (2022)
  363. Interaction between S4 and the phosphatase domain mediates electrochemical coupling in voltage-sensing phosphatase (VSP). Mizutani N, Kawanabe A, Jinno Y, Narita H, Yonezawa T, Nakagawa A, Okamura Y. Proc Natl Acad Sci U S A 119 e2200364119 (2022)
  364. PTEN redundancy: overexpressing lpten, a homolog of Dictyostelium discoideum ptenA, the ortholog of human PTEN, rescues all behavioral defects of the mutant ptenA-. Lusche DF, Wessels D, Richardson NA, Russell KB, Hanson BM, Soll BA, Lin BH, Soll DR. PLoS One 9 e108495 (2014)
  365. PTEN sequence analysis in endometrial hyperplasia and endometrial carcinoma in Slovak women. Gbelcová H, Bakeš P, Priščáková P, Šišovský V, Hojsíková I, Straka Ľ, Konečný M, Markus J, D'Acunto CW, Ruml T, Böhmer D, Danihel Ľ, Repiská V. Anal Cell Pathol (Amst) 2015 746856 (2015)
  366. Phosphatase and tensin homologue growth suppression without phosphatase. Stokoe D, Costello JF. Proc Natl Acad Sci U S A 102 2677-2678 (2005)
  367. Somatic PI3K activity regulates transition to the spermatocyte stages in Drosophila testis. Gupta S, Ray K. J Biosci 42 285-297 (2017)
  368. The C2 domain of calpain 5 contributes to enzyme activation and membrane localization. Bondada V, Gal J, Mashburn C, Rodgers DW, Larochelle KE, Croall DE, Geddes JW. Biochim Biophys Acta Mol Cell Res 1868 119019 (2021)
  369. Cancer: Precise control of localized signals. Stambolic V. Nature 522 38-40 (2015)
  370. Chemical and structural approaches to investigate PTEN function and regulation. Viennet T, Rodriguez Ospina S, Lu Y, Cui A, Arthanari H, Dempsey DR. Methods Enzymol 682 289-318 (2023)
  371. Concerted roles of PTEN and ATM in controlling hematopoietic stem cell fitness and dormancy. Fortin J, Bassi C, Ramachandran P, Li WY, Tian R, Zarrabi I, Hill G, Snow BE, Haight J, Tobin C, Hodgson K, Wakeham A, Stambolic V, Mak TW. J Clin Invest 131 131698 (2021)
  372. Expression, Purification, Crystallisation and X-ray Crystallographic Analysis of a Truncated Form of Human Src Homology 2 Containing Inositol 5-Phosphatase 2. Le Coq J, Heredia Gallego L, Lietha D. Protein J 35 225-230 (2016)
  373. FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA. Maiques O, Cuevas D, García Dios DA, Coenegrachts L, Santacana M, Velasco A, Romero M, Sónia G, Lambrechts D, Dolcet X, Amant F, Matias-Guiu X. Histopathology 65 371-388 (2014)
  374. Mouse model and human patient data reveal critical roles for Pten and p53 in suppressing POLE mutant tumor development. Park VS, Sun MJS, Frey WD, Williams LG, Hodel KP, Strauss JD, Wellens SJ, Jackson JG, Pursell ZF. NAR Cancer 4 zcac004 (2022)
  375. PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. Gomes CP, Andrade LA. Int J Gynecol Cancer 16 Suppl 1 254-258 (2006)
  376. PTEN is both an activator and a substrate of chaperone-mediated autophagy. Zhang KK, Burns CM, Skinner ME, Lombard DB, Miller RA, Endicott SJ. J Cell Biol 222 e202208150 (2023)
  377. Structure and mechanism of the unique C2 domain of Aida. Zheng LS, Liu YT, Chen L, Wang Y, Rui YN, Huang HZ, Lin SY, Wang J, Wang ZX, Lin SC, Wu JW. FEBS J 281 4622-4632 (2014)
  378. Another story of arginines in voltage sensing: the role of phosphoinositides in coupling voltage sensing to enzyme activity. Okamura Y. J Gen Physiol 134 1-4 (2009)
  379. Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms. Shen Z, Gu Y, Jiang R, Qian H, Li S, Xu L, Gu W, Zuo Y. Anal Cell Pathol (Amst) 2022 2522597 (2022)
  380. Case Reports Comprehensive Genomic Profiling for Therapeutic Decision and Identification of Gene Mutation in Uterine Endometrial Dedifferentiated Carcinoma. Taira Y, Shimoji Y, Arakaki Y, Nakamoto T, Kudaka W, Aoki Y. Case Rep Oncol 15 46-55 (2022)
  381. Expression, generation, and purification of unphosphorylated and phospho-Ser-380/Thr-382/Thr-383 form of recombinant PTEN phosphatase. Gajewski JE, Bird MJ, Crowhurst MO, Sio-Seng Lio D, Liu J, Wettenhall RE, Zhu HJ, Cheng HC. Protein Expr Purif 55 334-342 (2007)
  382. Inhibition of transfected PTEN on human colon cancer. Xu SS, Shen WL, Ouyang SY. World J Gastroenterol 10 3670-3673 (2004)
  383. Role of K364 next to the active site cysteine in voltage-dependent phosphatase activity of Ci-VSP. Paixao IC, Mizutani N, Matsuda M, Andriani RT, Kawai T, Nakagawa A, Okochi Y, Okamura Y. Biophys J 122 2267-2284 (2023)
  384. The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene. Garrido JAMG, Alcantara KMM, Danac JMC, Serrano FEC, Cutiongco-de la Paz EM, Garcia RL. Cells 10 3423 (2021)
  385. A novel PTEN mutant caused by polymorphism in cis-regulatory elements is involved in chemosensitivity in breast cancer. Wang J, Zhang S, Zhang J, Zhang Z, Ma Q, Fu W, Chen X, Zhao D, Zhao M, Di C, Xie X. Am J Cancer Res 13 86-104 (2023)
  386. Calculating the potential of C2 domains for membrane binding. Merithew E, Lambright DG. Dev Cell 2 132-133 (2002)
  387. Centriolar Protein C2cd3 Is Required for Craniofacial Development. Chang CF, Brown KM, Yang Y, Brugmann SA. Front Cell Dev Biol 9 647391 (2021)
  388. Computational and structure-guided design of phosphoinositide substrate specificity into the tyrosine specific LMW-PTP enzyme. Egbe E, Levy CW, Tabernero L. PLoS One 15 e0235133 (2020)
  389. Deciphering neuroprotective mechanism of nitroxoline in cerebral ischemia: network pharmacology and molecular modeling-based investigations. Vadak N, Borkar MR, Bhatt LK. Mol Divers (2024)
  390. Expression, purification and characterization of soluble red rooster laforin as a fusion protein in Escherichia coli. Brewer MK, Husodo S, Dukhande VV, Johnson MB, Gentry MS. BMC Biochem 15 8 (2014)
  391. Genetic analysis of DAF-18/PTEN missense mutants for the ability to maintain quiescence of the somatic gonad and germ line in Caenorhabditis elegans dauer larvae. Wittes J, Greenwald I. G3 (Bethesda) 12 jkac093 (2022)
  392. Novel anti-PTEN C2 domain monoclonal antibodies to analyse the expression and function of PTEN isoform variants. Torices L, Nunes-Xavier CE, López JI, Pulido R. PLoS One 18 e0289369 (2023)
  393. PTEN differentially regulates endocytosis, migration, and proliferation in the enteric protozoan parasite Entamoeba histolytica. Kadri S, Nakada-Tsukui K, Watanabe N, Jeelani G, Nozaki T. PLoS Pathog 18 e1010147 (2022)
  394. PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women. Gbelcová H, Gergely L, Šišovský V, Straka Ľ, Böhmer D, Pastoráková A, Sušienková K, Repiská V, Korbeľ M, Danihel Ľ, Priščáková P. Physiol Res 71 S125-S135 (2022)
  395. Semisynthetic Approach to the Analysis of Tumor Suppressor PTEN Ubiquitination. Iwase R, Dempsey DR, Whedon SD, Jiang H, Palanski BA, Deng B, Cole PA. J Am Chem Soc 145 6039-6044 (2023)
  396. Synthetic lethal approaches to target cancers with loss of PTEN function. Ertay A, Ewing RM, Wang Y. Genes Dis 10 2511-2527 (2023)
  397. Unraveling the Concealed Transcriptomic Landscape of PTEN in Human Malignancies. Boti MA, Adamopoulos PG, Vassilacopoulou D, Scorilas A. Curr Genomics 24 250-262 (2023)


Quick links